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We have investigated the properties of three sets of human missense genetic 
variations: cancer somatic mutations, monogenic disease causing mutations, and 
population SNPs, from the point of view of their impact on molecular function, 
distribution propensity in different protein structure environments, and disease 
mechanism.  
 
Cancer genome sequencing projects have identified a large number of somatic 
missense mutations in cancers. We have used two analysis methods in the SNPs3D 
software package to assess the impact of these variants on protein function in vivo. 
One method identifies those mutations that significantly destabilize three dimensional 
protein structure, and the other detects all types of effect on protein function, utilizing 
sequence conservation. Data from a set of breast and colorectal tumors were 
analyzed. In known cancer genes, approaching 100% of missense mutations are found 
to impact protein function, supporting the view that these methods are appropriate for 
identifying driver mutations. Overall, we estimate that 50% to 60% of all somatic 
missense mutations have a high impact on structure stability or more generally affect 
  
the function of the corresponding proteins. This fraction is similar to the fraction of 
all possible missense mutations that have high impact, and much higher than the 
corresponding one for human population SNPs, at about 30%. We found that the 
majority of mutations in tumor suppressors destabilize protein structure, while 
mutations in oncogenes operate in more varied ways, including destabilization of the 
less active conformational states. A set of possible drivers with high impact is 
suggested. 
 
We also studied a set of germline missense variants in phenylalanine hydroxylase, 
found in phenylketonuria (PKU) patients. With the aid of SNPs3D, we reinforced the 
previous finding that a high proportion of disease missense mutations affect protein 
stability, rather than other aspects of protein structure and function. We then focused 
on the relationship between the presence of these stability damaging missense 
mutations and the corresponding experimental data for the level and activity of the 
PAH protein product present under „in vivo‟ like conditions. We found that, overall, 
destabilizing mutations result in substantially lower protein levels, but with the 
maintenance of wild type like specific activity. The overall agreement between 
predicted stability impact and experimental evidence for lower protein levels is high, 
and in accordance with the previous estimates of error rates for the methods.  
 
We next investigated the involvement of missense single base variants in the interface 
between two interacting proteins and their role in disease. This work consisted of 
three steps: first, mapping of variants onto the protein structure and identification of 
those in the interaction interfaces; second, distribution enrichment analysis in three 
structure locations (protein interior, surface, and interface); and third, impact analysis 
with SNPs3D. Nearly a quarter of disease causing mutations are mapped onto protein 
interfaces, with a strong propensity for the heteromeric interfaces, indicating that 
interruption of functional contacts between proteins is a significant disease 
mechanism. We found the enrichment propensity in the interfaces is intermediate 
between protein surface and interior for all three types of variants considered, namely 
SNPs, inter-species variants, and disease mutations. We also found missense SNPs 
  
and inter-species variants share the same enrichment pattern, with a relatively high 
density on the protein surface and depletion in the interior. In contrast, the disease 
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Chapter 1: Introduction 
 
Section 1 Genetic Variations in the Human Population and Disease Susceptibility 
Subsection 1. Types of SNPs and Potential Impacts 
Single nucleotide polymorphisms (SNPs) are the most common type of genetic variations in 
human, accounting for about 90% of sequence differences.
1
 The latest release of the NCBI 
dbSNP database (version 132, http://www.ncbi.nlm.nih.gov/projects/SNP/), contains nearly 
20 million validated SNPs, of which about 11 million are near or in gene regions (from 2Kb 
upstream of the 5' UTR to 0.5Kb downstream of the 3' UTR). Since merely 1.5% of the 
nucleotides in the human genome code for proteins,
2
 approximately only 300,000 SNPs 
located in the coding region, on average about 15 SNPs per coding gene. Half of those coding 
SNPs are missense SNPs (150,000), which change an amino acid in a protein The rest of the 
SNPs in gene regions are synonymous variants, and those in introns (about 5 million), in 
regulatory regions, or in the 5‟ and 3‟ UTRs (Un-Translated Regions). These SNPs may 
impact mRNA splicing, messenger RNA structure, transcription regulation,
3
 or the interaction 
with microRNAs.
4
 The SNPs outside the gene regions are typically located in „functionless‟ 
regions of the genome. However, some lie in segments of sequence that show conservation 
between species, suggesting involvement in widespread function,
5
 such as sequences that 





Subsection 2. Monogenic Disease and Causal Mutations 
Traditionally, disease caused by genetic variations has been divided into two types: 
monogenic and complex trait disease. Of these, monogenic disease is better understood. It 
follows a Mendelian inheritance pattern, and is due to genetic variants in one (dominant) or 
both (recessive) copies of the disease gene. The Human Gene Mutation Database (HGMD)
6
 
collects the currently identified gene lesions underlying more than 1000 types of inheritable 
disease, most of which are rare monogenic disease. Of these lesions, approximately 70% are 
single base nucleotide changes, of which, 85% are missense (causing a single residue 
substitution) or nonsense (causes translation termination) mutations in coding regions, 14% 
are associated with splice sites, and 1% are in the regulatory regions. In other words, the 
majority of the known gene lesions that cause monogenic disease are missense variants.  
Although each monogenic disease is rare in the human population, the global prevalence of 
all monogenic diseases is high, approximately 3.6 in 1000 live births.
7
 12000 monogenic 
disorders and traits have been catalogued.
8
 One well studied monogenic disease is 
Phenylkentonuria (PKU), with an average prevalence of 1 in 10,000 live births. This disease 
is caused by inborn genetic alterations in the phenylalanine hydroxylase (PAH) gene resulting 
in lower gene activity in vivo. Over 500 genetic alterations have been catalogued from patient 
genotyping, of which over 300 are missense mutations. We will discuss some of these 
missense mutations in detail in Chapter 3. 
 
Subsection 3. Relationship between SNPs and Complex Trait Disease 
Complex trait disease or common disease, such as heart disease, diabetes, high blood 
pressure, asthma, and cancer, does not show a classic Mendelian inheritance pattern. 
Traditional linkage analysis for finding the causal mutations in monogenic disease is not 






With the completion of human genome sequencing,
2; 10
 and the discovery of a large number 
of SNPs in the human population,
11; 12; 13
 new methods have been developed to study how 
genetic variations relate to increased complex trait disease susceptibility. A successful 
strategy for finding high-risk loci in complex trait disease is by performing a Genome wide 
association study (GWAS). The basic idea is to compare the prevalence of a large set of SNPs 
(usually by using SNP chips), between a set of disease patients and a set of control subjects. 
For example, the WTCCC (Wellcome Trust Case Control Consortium) performed a series of 
GWAS studies on 24 types of common disease with over 116 thousand disease samples 
through an international collaborative network (https://www.wtccc.org.uk). Based on the 




GWAS studies have so far identified several hundred genetic markers with different levels of 
occurrence in disease and control groups.
15
  The chip-based technology restricts GWA studies 
to those common SNPs (usually those with minor allele frequencies (MAFs) above 5%). 
However, the proportion of phenotypic variation explained by such common SNP loci is very 
small (<10%) for nearly all examined common disease,
15; 16
 suggesting other genetic factors 
play a major role. The missing heritability of complex disease has invoked in depth 
discussion. The following genetic factors should be considered for underlying causes: rare 
single nucleotide allele (MAF<1%), large scale variants (deletions, duplications, and 
inversions), copy number variations (CNV), non-coding RNAs, epigenetic effects, complex 
genetic architecture and epistasis.
17; 18
 In addition, gene–environment (G×E) interactions may 
add a complication in explaining the missing heritability. The role of rare single base variants 
has been emphasized, although the exact contribution to common disease is still under 
discussion.
16; 17; 18; 19
  Encouraging results show that a combination of GWAS and the latest 
genome sequencing technology does identify some rare variants with large effect size in in 
common disease susceptibility.
16; 20





Subsection 4. Impact Analysis of Genetic Variations and their Relationship to 
Disease susceptibility 
A variety of computational methods have been developed to study the relationship between 
genetic variations and disease. The majority focus on the impact of genetic variations at the 
protein level, rather than at cellular or organismal level. And so far only missense mutations 
which change residue types in protein sequence have been successfully examined. Typically, 
two major aspects of impact have been investigated. One is on protein function, including, for 
example, interaction with other proteins or DNA/RNA, catalytic efficiency, ligand binding 
affinity, and post-translational modification. The other is on protein thermodynamic stability, 
which can be examined through scrutinizing the detailed atomic level of protein structure. 
Correspondingly, the computational methods developed so far fall into two categories. One 
popular strategy is to survey the sequence conservation at a residue position, using the 
multiple sequence alignment of the protein family. The second strategy is to model an amino 
acid substitution in the context of the protein structure and examine its effect on a number of 
factors affecting stability, such as hydrogen bond loss, steric clash with neighboring atoms, 
and electrostatic repulsion. The sequence-based strategy has wider applicability and is 
sensitive to most factors affecting protein function and stability, but does not provide any 
insight into specific molecular mechanism. The structure-based strategy can provide 
mechanism information at the atomic level, but only for stability effects, and its use is 
restricted by the limited availability of protein structure. In several studies, these two 
strategies are combined. 
21; 22; 23; 24; 25
 Parameters representing sequence conservation or 
stability factors are usually used to train a machine learning classifier (such as a Support 
Vector Machine
25
 or Random Forest
26
) or a probability model,
23; 27
 which is then applied to 
















); and the second set of low-impact or neutral variants from mutagenesis 
experiments,
27
 variations fixed between human and closely related mammals,
23; 32





Subsection 5. SNPs3D: SNP Impact Analysis Methods from Our Lab 
Our lab has developed two models (SNPs3D),
32; 33
 which are able to identify those missense 
single base changes (i.e. those that change an amino acid) that have the most deleterious 
impact on protein function or stability in vivo. In the stability model, a set of 15 stability 
impact factors is used to describe the structural effect of a residue change in the three 
dimensional structure. Some factors are continuous quantitative measures, for example 
electrostatic interactions and packing, while others are binary classification measures 
(significantly stabilizing or not), for example, introduction of backbone strain. Using these 15 
features, a support vector machine (SVM) model was trained on a set of human mutations 
causative of disease, and a control set of non-disease sequence variations fixed in other 
species. This model identifies 74% of disease mutations, with a false positive rate of 15%. 
The other model makes use of sequence conservation information in protein families to assess 
the functional and structural importance of residues altered by missense variants. The basis of 
this method is that the variability of the amino acids observed at a particular position strongly 
reflects the strength of functional and structural restraints operating at that position in the 
protein. Hence, the more critical a position for stability or protein function, the more 
restricted the set of amino acids throughout the protein family. The SVM model included five 
measures of residue conservation, and was trained with similar data to that for the stability 




rate of 10%. In application of these methods, after carefully controlling for errors, it was 
found that approximately one quarter of known human missense SNPs are deleterious.
32; 34
 
Most of these deleterious SNPs are not involved in monogenic disease. It was proposed that 
robustness of the protein network prevents most such SNPs from having a direct phenotypic 
impact, often in a non-linear way. The interaction between multiple deleterious SNPs in a 
protein network is likely related to the nature of human complex disease traits. 
 
 
Section 2 Cancer Somatic Mutations and Oncogenesis 
The genetic variants discussed in the previous section are all germline variants, which are 
most likely to have arisen in gametogenesis due to germline cell division. Germline variants 
are heritable and can be detected in all differentiated cells in a descendant. In contrast, in 
higher eukaryotes, cells other than germline acquire spontaneous mutations during division, 
which are called somatic mutations and are not heritable. It‟s believed that cancer is 
principally caused by a sequential accumulation of genetic alterations in a group of cells in 
specific tissues, together with environmental factors.
35; 36; 37; 38
 
 
Subsection 1. Progress in Cancer Genome Sequencing 
More than 30 years ago, retroviral oncogenes (RAS genes) were discovered to cause 
tumors in animals.
39
 Subsequently, somatic mutations in the KRAS gene were found 
in about 40% of colorectal cancers.
40
 Soon after, genes sharing the same pathway 
with KRAS, such as PI3K (phosphoinositide-3-kinase) and RAF (RAF proto-
oncogene serine/threonine-protein kinase), were found to harbor mutations that 
contribute to tumor development. To search for more cancer-related mutations, large-






 sequenced 518 protein kinases in a set of tumors. At the same time, 
whole genome sequencing of coding sequences was performed to look for candidate 
cancer genes throughout the human genome.
41; 42; 43; 44; 45; 46; 47; 48; 49
 With the advance 
of Next-Generation Sequencing technology, complete cancer genome sequencing is 
becoming possible, and will provide data not only for single nucleotide variations but 
also for large-scale chromosomal structure variations and copy number variations.
50; 
51; 52; 53; 54; 55
 Sequencing studies have already identified thousands of genetic 
alterations, providing us a genetic landscape of tumors. A major post-sequencing 
challenge is to distinguish oncogenic driver mutations from random background 
mutations, arising from the increased rate of cell division and impaired DNA repair 
machinery. 
 
Subsection 2. Identification of Cancer Genes 
Since the discovery of the first cancer gene, KRAS, a list of genes have been annotated as 
tumor contributive, sometimes type specific.
38; 56; 57
 Based on the relationship between the 
activity change of a gene product and its molecular function in the tumorigenesis process, 
tumor related genes are classified into oncogenes and tumor suppressor genes. Specific 
somatic mutations in oncogenes or abnormal over expression promote tumor development. 
For example, KRAS is conditionally activated upon GTP binding. The mutations at the Gly-
12 position restrict KRAS inactivation, which leads to constitutive activation of the 
RAS/MAPK pathway, and consequently uncontrolled cell proliferation.
40
 Oncogenic 
mutations exert an opposite effect on tumor suppressor genes than on oncogenes – reducing 
the activity of the gene products. For example, a normal function of transcription factor TP53 




genes upon cellular stress.
58; 59
 Deleterious mutations have been found in TP53 in 
approximately 50% of various types of tumor.
60
  
Mutations in these cancer genes are referred as driver mutations, in contrast to the others that 
hitch-hike in clonal expansion.
61
 Driver mutations in oncogenes mostly act in a dominant 
manner, while in tumor suppressors they are usually observed as recessive. There are varied 
ways to activate an oncogene or inactivate a tumor suppressor in different situations, such as 
changing the expression level, removal of its regulator, or alteration of its molecular function 
(such as loss of DNA binding). 
Since it‟s believed that driver mutations are positively selected in tumor development, 
mutation prevalence is widely used to identify cancer genes in addition to expression 
changes.
38
 Statistical models are designed to look for mutation-enriched genes by comparing 
the expected number of mutations per nucleotide or the expected ratio of 




Subsection 3. The Role of Impact Analysis in Identifying Cancer Genes 
Computational impact analysis of single residue changes on gene activity compliment 
frequency based methods of identifying driver genes, and in addition, can provide 
information on molecular mechanism. As mentioned earlier, several computational methods 
have been developed to evaluate the functional and/or structural impact of a germline variant, 
including two models contributed by our lab.
32; 33
 Recently, two methods using machine 
learning classification have been developed specifically for identifying cancer somatic driver 
mutations.
63; 64
 Both used frequently observed somatic mutations catalogued in the COSMIC 
database
65
 as the positive set, which are regarded as cancer-associated. For the control set, 
Carter et al
63
 used in silico generated random mutations based on the tumor type and di-
nucleotide dependent context. Kaminker et al
64




As described earlier, the SNPs3D software suite consists of two independent modules for 
analyzing the impact of missense substitutions on protein function: a conservation-based 
sequence profile method that is able to detect all possible types of impact on the protein 
function and structure integrity, and a specific structure-oriented stability method that can 
identify impact caused by structure changes at the atomic level. As described in Chapter 2, 
we have used these methods to examine a set of missense somatic mutations found in cancer 
samples. The hypothesis underlying this application is that driver missense mutations will 
have a strong impact on in vivo protein activity, and thus general molecular impact analysis 
methods will be suitable for identifying them. Compared to impact methods trained 
specifically on cancer data, these methods should have the advantage of providing more 
direct information on molecular function, and allowing cancer missense mutations to be 
placed in the context of other types of missense variants, such as those found in monogenic 
disease and population SNPs. 
It should be noted that  other high throughput technologies are being used to identify 
chromosomal rearrangements, such as large-scale chromosomal DNA amplification, 
homozygous deletion, inversion, and inter-chromosomal translocation.
66; 67; 68
 These large 
scale changes will have multiple impacts on gene function.. So far, there are no 
computational methods that utilize this information to model cancer progress. 
 
Section 3 Protein-Protein Interaction Interfaces 
Subsection 1. Protein complexes and disease 
Understanding disease mechanism at the molecular level is greatly expedited by examining 
the  impact of a causal mutation in the structure context.
69
 Increasing knowledge of the 




of genetic variation in protein interaction interfaces and the relationship of these to disease 
susceptibility. The major directions in studying protein interactions and disease mechanism 
from a structural perspective have been reviewed by Kann.
70
 Several studies have discussed 
the structural distribution of disease missense mutations, including mapping these onto the 
structure of protein complexes. Steward et al
71
 and Vitkup et al
72
 agreed that disease 
mutations are more likely in the buried core region rather than on exposed protein surface. 
Further, Ye et al
73
 suggested the disease mutations on the surface tend to cluster into patches, 
whereas that effect is not seen for nonsynonymous SNPs. Ye speculated that such patches are 
located at or close to protein interaction interfaces. Bateman and colleagues
74
 found that  over 
1400 known disease mutations can be mapped to protein interfaces. In chapter 4 we present 
the first analysis of the prevalence of different classes of genetic variant in interfaces, 
compared with other protein environments. 
 
Subsection 2. Types of Interface and Their Properties 
There are several ways to classify protein-protein interactions from a structural point of 
view.
75
  Taking into consideration the classifications adopted in previous studies, the 
following distinctions are made in this thesis. 
- Homomeric or heteromeric describe interactions occurring between identical or non-
identical polypeptide chains respectively. Homomeric complexes are usually formed 
with structural symmetry between monomers. 
- Transient and obligate complexes. In an obligate interaction, the protomers are not 
found as stable structures on their own in vivo, e.g. DNA helicase. In transient 
complexes such as intracellular signaling complexes, antibody-antigen, receptor-




Subsection 3. Large Scale Identification of Protein-Protein Interactions 
The development of high-throughput experimental technologies such as yeast two-hybrid 
systems (Y2H),
76
 Tandem Affinity Purification (TAP) with subsequent mass spectrometry 
identification,
77; 78
 and protein chips,
79
 have led to the generation of large protein-protein 







these data have high false positive and false negative rates, evidenced by a low level of 
consensus among the results obtained by different identification methods.
82
 
In addition to experimental methods, a number of „high throughput‟ computational 
approaches have also been developed to detect protein-protein interactions: 
- Conservation of gene neighborhood.83 In prokaryotes, functionally related proteins, 
such as in operons, tend to cluster together in chromosomes. The method is not 
applicable to eukaryotes.  
- Gene fusion events.84; 85 Sometimes interacting proteins fuse to become part of a 
single gene in other species. 
- Similarity of phylogenetic trees. Interacting protein pairs tend to co-evolve, so that 




- Correlated mutations (In silico two-hybrid method).88 Also based on co-evolution of 
interacting proteins.  
- Structural features and interface residue conservation.89; 90; 91; 92  
- Correlated mRNA expression. If two genes share similar patterns of mRNA 
expression in  different conditions or experiments, there may be a functional 






- Homology inference. If two proteins are known to interact, close homolog pairs may 
also do so.
94; 95
 Homology modeling is performed to interrogate the complex structure 
of the unknown  interaction. 
 
Subsection 4. Progress in Understanding Protein-Protein Interactions 
The structural features and residue propensities at interfaces have been investigated, with the 
aim of understanding the principles governing protein interactions. Studies range from an 
individual complex
96
 to a set of more than 100 non-redundant complexes.
75; 97; 98; 99; 100
 
Structural features such as solvation potential, hydrophobicity, planarity, protrusion, atom-
pair frequencies across interfaces, residue interface propensity, packing density and 
accessible surface area have been explored. Binding sites are described as mainly 
hydrophobic, planar, circular, and protruding,
97; 98; 101; 102 
and are composed of relatively large 
surfaces (average 800 Å
2
) with good shape and electrostatic complementarily.
97; 98
 No single 
feature is sufficiently pronounced that it can be used to distinguish between interface and 
non-interface surface residues. However, some success has been achieved when features are 
used in combination.
103; 104
 Analysis of features such as interface size, polarity, hydrogen 
bonding, residue composition and packing density between intra-chain and inter-chain 




A number of properties derived from analysis of homologous protein families, such as amino 
acid conservation at protein-protein interaction interfaces
89; 90; 91
 and correlated substitutions 
for residues which are in contact across interfaces
88
 have proved to be useful in the prediction 
of interface residues in a number of studies.
89; 92; 106; 107; 108; 109
 Early studies showed that 
interface residues are more conserved than other surface residues,
110
 and the most buried 
interface residues are almost as conserved as residues in the protein interior.
91




are limited to homo-oligomeric proteins and based on a small dataset. More recent studies 
include different types of interface and use larger datasets. For example, Weng‟s group
111
 has 
suggested that conservation scores differ significantly for residues at interfaces and other 
parts of the protein surface for both transient and obligate complexes. 
A different type of information comes from biochemical studies such as alanine-scanning 
mutagenesis, in which interface residues are mutated to alanine one at a time and binding 
properties measured. ASEdb
91
 is a compilation of single alanine mutations in protein-protein 
interactions and protein interactions with other biomolecules such as DNA.  These studies 
have shown that a subset of residues is often dominant in determining the strength of a 
protein-protein interaction.
112; 113; 114
 In particular, there are hot spot residues, defined as those 
where mutation to alanine significantly decreases binding affinity (more than 2 Kcal/mol). 
There are amino acid preferences for hot spots,
115
 with Trp, Arg, and Tyr the three most 
common residues. Further, it has been shown that the hot spots correlate well with 
structurally conserved residues
71; 116













Chapter 2: Structural and Functional Impact of Cancer Related 
Missense Somatic Mutations 
 
Section 1 Abstract 
A number of large scale cancer somatic genome sequencing projects are now identifying 
genetic alterations in cancers. Evaluation of the effects of these mutations is essential for 
understanding their contribution to tumorigenesis. We have used SNPs3D, a software suite 
originally developed for analyzing non-synonymous germ line variants, to identify single 
base mutations with a high impact on protein structure and function. Two machine learning 
methods are used, one identifying mutations that destabilize protein three dimensional 
structure, and the other utilizing sequence conservation, and detecting all types of effects on 
in vivo protein function. Incorporation of detailed structure information into the analysis 
allows detailed interpretation of the functional effects of mutations in specific cases. Data 
from a set of breast and colorectal tumors were analyzed. In known cancer genes, 
approaching 100% of mutations are found to impact protein function, supporting the view 
that these methods are appropriate for identifying driver mutations. Overall, 50% to 60% of 
all somatic missense mutations are predicted to have a high impact on structural stability or to 
more generally affect the function of the corresponding proteins. This value is similar to the 
fraction of all possible missense mutations that have high impact, and much higher than the 
corresponding one for human population SNPs, at about 30%. The majority of mutations in 
tumor suppressors destabilize protein structure, while mutations in oncogenes operate in more 
varied ways, including destabilization of the less active conformational states. The set of high 





Section 2 Introduction 
Systematic cancer genome resequencing projects are now providing a large amount of 
information on somatic mutations in cancer tissues and cell lines.
41; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52
 
These data have already led the identification of a number of previously unknown cancer 
genes.  
In a seminal early study,
48; 49
 Wood and colleagues sequenced 20,857 transcripts from 18,191 
human genes in 22 breast and colorectal tumors, followed by resequencing of genes where 
mutations were found in an additional 48 samples.
48; 49
 After removal of known germ line 
SNPs, 1963 distinct somatic missense (non-synonymous) single base mutations remain, 
accounting for ~80% of measured mutations, with nonsense mutations and small indels 
constituting the remainder. Although additional data types, including non-coding sequence 
alterations, copy number changes, and DNA methylation will expand this picture, it is already 
clear that missense mutations play a major role. In the Wood el al data, only 18 mutations are 
found in more than one patient, and mutations are located in a total of 1498 transcripts from 
1486 genes. Thus, mutations are consistently found in a few genes, but there is a long tail of 
genes in which mutations have been found occasionally, or only in one sample, and it is far 
from obvious from the mutation profiles which genes are involved in contributing to the 
virulence of the disease. The analysis included the use of two computational methods to 
identify a set of high impact mutations. In this work, we have performed a more detailed 
analysis of the Wood et al. data, placing particular emphasis on the structural mechanisms by 
which potential driver mutations affect protein function. 
Two classes of approach have been developed to specifically address the issue of which 
cancer mutations are drivers. One class of methods makes use of the distribution and type of 
cancer mutations, including the density of mutations in specific genes
48; 49; 118




synonymous to non-synonymous mutations to identify selection pressure on particular 
genes
41; 62
. The second class of methods groups genes in which cancer mutations occur into 
pathways or gene networks.
119; 120
 These methods have been successful in identifying a 
number of novel candidate genes and pathways.  
An additional more general class of methods that may used to identify potential drivers assess 
the protein functional and structural consequences of amino acid changes resulting from 
single base substitutions, using machine learning methods. A number of methods have been 
developed (for example, see references
21; 22; 23; 24; 27; 32; 33; 121
), usually aimed at interpreting 
germ line variations.  Amino acid substitutions impact in vivo protein function in a variety of 
ways. Protein thermodynamic stability or folding efficiency may be affected, resulting in a 
reduced level of protein. Aspects of protein function, including ligand binding affinity, 
catalytic efficiency, allosteric effects, and post-translational modification, may also be 
impacted. The methods fall into two main categories. The simplest exploits the principle that 
the more conserved the type of amino acid across a protein family at a specific position, the 
more likely it is that uncommon substitutions will have a functional impact of some kind. 
Sequence conservation, the position specific substitution pattern, and the similarity of 
residues‟ physiochemical properties are often used as input measurements to a machine 
learning classifier, such as a support vector machine (SVM)
32; 122
 or a Bayesian probability 
model
27; 121
. These methods are widely applicable, requiring only a reasonably diverse set of 
sequences for the corresponding protein family. They have the disadvantage that they provide 
no insight into the nature of the underlying functional effect. The second category of methods 
examines the three dimensional structural consequences of an amino acid substitution to 
determine whether there is a substantial impact on stability or folding.
22; 23; 24; 25; 33
 An 
experimentally determined protein structure or an adequately accurate structure model is 
required, restricting the range of application. A number of structural features may be 




electrostatic effects, and steric clashes. As with sequence based methods, these data are input 
to an appropriate classifier. Use of structural information also provides direct insight into the 
role of changes in molecular function, such as ligand binding, catalysis and regulation. A 
range of training data are used for these classifiers, such as data from laboratory site-directed 
mutagenesis experiments
27





 SWISSPROT database disease annotation.
22; 23; 24
 Control data are often obtained 
from residue variants fixed during divergence of human and a closely related species
23; 32
 or 
by assuming that common human SNPs are of low impact
21; 22
. Some methods combine 
sequence and structure information in a single classifier.
21; 22; 23; 24; 25
 
Two studies of cancer mutations using this class of methods have already been reported.
63; 64
 
One of these methods also includes other factors, such as mutation density, derived from 
cancer data.
63
 We have used protein structure and sequence analysis methods, with particular 
emphasis on interpretation of mutations in structural terms, where possible. The SNPs3D 
suite
32; 33
 contains two separate analysis procedures, both utilizing a support vector machine. 
The first incorporates a thorough analysis of the features of protein structures that may affect 
thermodynamic stability or protein folding efficiency, and utilizes a full atom level 
description of protein structure.
33
 Experimental protein structure is used where possible, 
supplemented by the judicious use of high quality comparative models. The experimental 
structures and models are also used to more broadly interpret all aspects of the functional 
impact of the mutations in specific cases. The second method is based on the level of 
sequence conservation within the relevant protein family.
32
 Both methods were trained with a 
set of missense mutations that cause monogenic disease, extracted from the Human Genome 
Mutation Database
6
 (HGMD), and a control set of single residue changes fixed between 
closely related mammalian species.  
The methods have been extensively benchmarked and tested. The stability analysis, though 




measurements of changes in thermodynamic stability.
33
 It has also been shown to be 
consistent with cell assay data for a set of mutations leading to the monogenic disease 
phenylketonuria (PKU) (unpublished). A blind test of both methods against experimental data 




Training on monogenic disease mutations results in methods that detect relatively large 
changes in in vivo protein function. The methods have previously been applied to the set of 
monogenic disease single base mutations
33
 and to a set of germ line missense SNPs
32; 33
. 
About 25% of these SNPs are found to have a high impact on the in vivo function of the 
corresponding proteins.
32
 Approximately, 70% of monogenic disease mutations and 60% of 
high impact germ line missense SNPs act through destabilization of protein three dimensional 
structure, rather than via direct effects on molecular function. 
The principle underlying the use of these methods for multiple types of missense substitution, 
including cancer mutations, is that the mechanisms by which missense variants affect protein 
function are universal, and independent of the phenotypic consequences. Thus, any method 
trained to detect high impact on molecular function should be appropriate. In support of this 
view, one study
64
 has found that the distributions of scores for cancer mutations and 
Mendelian disease mutations, obtained using a general sequence profile method
27
, are similar. 
We explore that hypothesis, showing that most known driver mutations are high impact, and 
use the methods to provide a set of possible driver mutations in the survey data. We also 
establish that destabilization of three dimensional structure is the major molecular mechanism 




Section 3 Results 
Subsection 1. Experimental Data 
The analysis was performed on combined data from two studies of colorectal and breast 
cancer mutations,
48; 49
 including mutations in 20,857 transcripts from 18,191 genes. These 
studies consisted of two steps – an initial Discovery screen in which all exons were 
sequenced in 11 colorectal cancer samples and 11 breast cancer samples, and a second 
Validation screen, in which the exons from all genes with one or more mutations identified in 
the Discovery step were sequenced in an additional set of 24 tumor samples for each cancer 
type. Combining both screens from both studies,
48; 49
 1963 distinct somatic missense 
mutations were found, only 18 of which were observed in more than one patient. The mutants 
are located in a total of 1498 transcripts from 1486 genes. Noticeably, the average number of 
mutants per gene is small – slightly greater than one. The authors of these studies identified 
140 likely candidate genes (CAN genes) for each tumor type, providing 273 distinct genes 
altogether. These genes are those where at least one non-synonymous mutation was found in 
both screens and are in the highest range of average mutations per nucleotide. 
The sequence profile and the structure stability methods were used to estimate the impact of 
these 1963 missense mutations on protein structure and function, and the results were 
compared with those of two others methods
22; 27
 included in the original analysis.
49
 The 
sequence profile analysis could be applied for 84% of the mutations (1654 mutations 
analyzed), (The other 16% of mutations have too shallow a sequence alignment or too gappy 
an alignment.) Only about 15% of mutations (284 analyzed) had sufficiently accurate 




Subsection 2. Mutations in Known Cancer Related Genes 
A number of genes have previously been implicated in tumor development.
38
 Presumably, a 
high impact mutation found in a cancer sample and in such a cancer related gene is very 
likely to be a 'driver' mutation, providing a means of evaluating the effectiveness of the 
classification methods at identifying drivers. We examined mutations in the survey data
48; 49
 
in three sets of annotated cancer related genes and also in the 273 „CAN‟ candidate cancer 
genes identified by the survey authors.
49
 The three sets are: the „NCBI CAN‟ list, consisting 
of those genes for which the terms „oncogene‟ or „tumor suppressor‟ occurs in the gene 
summary in the NCBI Entrez Gene database (65 tumor suppressors and 230 oncogenes); the 
„Sanger census‟ set from the cancer census gene review (362 genes);
38
 and the „Fsearch‟ set 
obtained by in-house literature mining (278 genes). The latter procedure compiles a word and 
phase profile for all PubMed abstracts containing at least one cancer gene name (in this 
instance, the oncogenes and tumor suppressor genes in the „NCBI CAN‟ gene list), and 
utilizes this cancer specific profile to identify other candidate genes based on the similarity of 
their PubMed abstract profiles.
32
  
The Venn diagrams in Figure 2.1a and 2.1b show the number of survey genes and somatic 
mutations in each set and the overlap across the three sets. There are rather few shared genes, 
and a substantial fraction of mutations (~25%) occur in just six common genes (APC, TP53, 










Figure 2.1. Three sets of known cancer genes used in the analysis.  
(a) Gene set overlap: 24 genes are common to all three sets, out of a total of 822. (b) 
Distribution of somatic missense mutations over the three cancer gene sets (number of genes 
in brackets). Approximately half of the mutations in each set also occur in at least one other 
set. 36 mutations (25% of the total) in just six genes are common to all three sets. More detail 








Figure 2.2a shows the fraction of survey mutations assigned a high impact on protein 
function, using four different methods: our Profile,
32
 and Stability methods,
33
 and those 




 There are relatively few 
mutations in each set, but a consistent picture emerges. For these known cancer genes, a very 
high fraction of mutations are found to have a high impact on protein function or structure, 
establishing that the methods are all effective at identifying drivers and that drivers usually 
have a high impact on molecular function. Further, where structure is available, a high 
fraction of these apparent drivers are found to be associated with a loss of protein three 
dimensional structure stability. After correction for false positive and false negative rates (see 
Methods), all four methods return 100% high impact for the „NCBI CAN‟ set, and three do so 
for the „Fsearch‟ set. The lowest high impact fraction is 80%, for the Profile method on the 
„Sanger census‟ set. For the „NCBI CAN‟ set tumor suppressors and oncogenes can be 
considered separately, Figure 2.2b shows that the corrected fractions for tumor suppressors 
are all 100%, The values for oncogenes tend to be somewhat lower, but are still large (77 – 
95%).  For tumor suppressors, almost all mutations are assigned as destabilizing to protein 
structure, and so are a substantial number of mutations in oncogenes. (Full data are in 
Supplementary Table S2.2.) The high fraction of destabilizing mutations in oncogenes is 






Figure 2.2. Fraction of high impact mutations in three sets of cancer related genes.  
(a) Fraction of all missense mutations that are assessed as having a high impact on protein 
function, by four different methods. The solid bars show high impact fractions, and the open 
bars show the additional high impact fraction after correcting for estimated false positive and 
false negative rates. All methods show a very large fraction of somatic mutations in known 
cancer genes are high impact, often approaching 100%.  
(b) High impact fraction for mutations in tumor suppressors and oncogenes in the NCBI CAN 
set. Corrected impact fractions are all 100% for tumor suppressors, about 10 – 20% lower for 
oncogenes. These results show the different methods are all effective at identifying the driver 
mutations in these genes.  








In known tumor suppressors in the „NCBI CAN‟ set, of the 26 high impact missense 
mutations assigned by the Profile method, 21 are homozygous. The fraction is slightly higher 
for destabilizing mutations (19 homozygous out of 22 destabilizing mutations). For 
oncogenes, the fraction of homozygous mutations is lower (5 out of 14 for the Profile method 
and 5 out of 8 destabilizing mutations). For all three cancer sets, the overall level of 
homozygosity is 39%. The rate for indels, usually involving loss of function, is 56%. Thus, 
homozygosity appears a common property of these driver mutations, especially when loss of 
function is involved. A survey of a larger collection of cancer mutations in COSMIC found a 




Subsection 3. Analysis of Mutations in Known Cancer related Genes 
Tables 1a and 1b show the detailed analysis of mutations in the known tumor suppressors and 
oncogenes in the „NCBI CAN‟ gene set, for those with both Profile and Stability results. For 
tumor suppressors, we find that 22 of the 25 mutations destabilize the corresponding proteins. 
Figure 2.3 (a-c) shows the structural context for three destabilizing mutation examples: 
V157F in TP53, D300V in SMAD2, and R361H in SMAD4. Full stability impact details are 






Table 2.1. Impact analysis of missense mutations in known cancer associated genes 
(mutations with structural information in the NCBI CAN set).  
For each mutation, the impact classification values are shown. A red, negative value indicates 
a high impact mutation, a black, positive value, a low impact or neutral mutation. For 
example, TP53 P177R is classified as high impact (-2.47) by the Profile method and low 
impact (+0.67) by the Stability method. (a) 25 mutations in four tumor suppressors. The 
majority of the mutations in these tumor suppressors act by destabilizing protein structure, 
resulting in a lower in vivo level of protein. (b) 12 mutations in five oncogenes. More than 
half of mutations are also classified as destabilizing, likely involving allosteric regulation. All 
of these mutations in known cancer genes are classified as high impact. 
 
 
Table 2.1(a) Mutations in known tumor suppressors 




Molecular mechanism Stability impact 
TP53 P177R -2.48 0.67 disrupts interaction with 
TP53BP1 
on surface  
TP53 R248Q -1.80 0.81 disrupts DNA binding on surface 
TP53 R248W -2.83 0.81 disrupts DNA binding on surface 
PTEN A86P -0.17 -0.40 lowers in vivo protein 
concentration 
loss of hydrogen bond and 
backbone strain 
SMAD2 D300V -0.99 -1.38 lowers in vivo protein 
concentration 
overpacking, loss of 
hydrogen bond and saltbridge 
SMAD4 P130S -0.83 -1.18 lowers in vivo protein 
concentration 
loss of hydrophobic effect, 
buried polar residue 
SMAD4 D351N -0.65 -0.64 lowers in vivo protein 
concentration 
loss of saltbridge 
SMAD4 R361H -2.02 -0.67 destabilizes homo or 
hetero complex 
loss of saltbridge 
TP53 F134L -0.67 -1.18 lowers in vivo protein 
concentration 
loss of saltbridge 
TP53 V157F -0.77 -1.05 lowers in vivo protein 
concentration 
overpacking 
TP53 R175H -2.48 -1.29 lowers in vivo protein 
concentration 
overpacking, loss of 
hydrogen bond and saltbridge 
TP53 H193R -2.83 -1.13 lowers in vivo protein 
concentration 
loss of saltbridge 
TP53 R213P -2.84 -1.05 lowers in vivo protein 
concentration 
loss of hydrogen bond 
TP53 S241F -3.17 -0.38 disrupts DNA binding on surface 
TP53 C242F -3.17 -1.00 lowers in vivo protein 
concentration 
overpacking, Zn binding 
disruption 
TP53 R249S -2.48 -1.57 lowers in vivo protein 
concentration 
loss of hydrogen bond and 
saltbridge 
TP53 R267W -2.83 -1.13 lowers in vivo protein 
concentration 
overpacking, loss of 
hydrogen bond 
TP53 E271K -2.14 -1.09 lowers in vivo protein 
concentration 
loss of saltbridge 






TP53 R273H -1.11 -0.58 lowers in vivo protein 
concentration; disrupts 
DNA binding 
loss of hydrophobic effect, 
loss of hydrogen bond 
TP53 R273L -2.83 -0.99 lowers in vivo protein 
concentration; disrupts 
DNA binding 
loss of saltbridge 
TP53 P278S -2.83 -1.46 lowers in vivo protein 
concentration 
loss of hydrophobic effect, 
buried polar residue 
TP53 R280I -3.17 -0.85 lowers in vivo protein 
concentration; disrupts 
DNA binding 
overpacking, loss of 
saltbridge 
TP53 D281H -2.48 -0.86 lowers in vivo protein 
concentration 
electrostatic repulsion 
TP53 Y163C 0.30 -1.99 lowers in vivo protein 
concentration 






Table 2.1(b) Mutations in known oncogenes 
 




Molecular mechanism Stability impact 
RAB38 K111T -0.27 0.15 unclear; could involve 
interaction with GEF 
 
KRAS G12A -0.71 0.97 impedes binding of 
rasGAP 
 
KRAS Q61R -0.32 1.05 switch II region; affects 
nucleotide exchange 
on surface 
BRAF V600E -0.59 0.25 negative charge results in 
kinase activation 
on surface 
KRAS G12D -2.08 -0.54 impedes binding of 
rasGAP 
overpacking with Q61 
KRAS G12V -1.74 -1.26 impedes binding of 
rasGAP 
overpacking with Q61 
KRAS G13D -2.32 -1.65 affects nucleotide binding 
and exchange 
backbone strain and 
overpacking 




KRAS A146T -1.63 -0.13 affects nucleotide binding 
and exchange 
 
NUP214 G424A -1.55 -0.20 unclear destabilizes inter-domain 
linker, backbone strain 
RAB5C R40H -1.76 -0.59 affects nucleotide binding 
and exchange 
destabilizes peptide 
upstream of switch I 
KRAS G12S 0.32 -1.30 impedes binding of 
rasGAP 







The observation of a high fraction of destabilizing mutations for the tumor suppressors is 
similar to that for mutations which cause monogenic disease, where approximately 70% 
appear to act by destabilizing protein structure.
33
 Although the exact mechanism of action in 
vivo is not established in most cases, it is likely that less stable proteins have a shorter half 
life, or that folding and transport are affected, in both cases resulting a lower in vivo protein 
concentration.  
The three tumor suppressor mutations not predicted to affect protein stability are all assigned 
a high impact by the Profile method, and therefore likely affect function in some way other 
than via protein stability. R248 in TP53, a hot spot for cancer mutations,
65
 has substitutions 
R248W and R248Q. TP53 functions as a transcription factor involved in cell cycle regulation 
and R248 forms a charge-charge interaction with a DNA backbone phosphate, and these 
mutants obviously disrupt this electrostatic interaction, weakening the binding (Figure 2.3d). 
P177R in TP53 lies in a region of the surface that interacts with the C terminal BRCT1 
domain of TP53BP1 (P53 binding protein 1). Normally, TP53BP1 binds to TP53 in response 
to DNA damage, leading to activation of P21 transcription.
124
 The mutant causes a steric 
clash, destabilizing this protein-protein interaction. (Picture not shown) 
Eight of the 12 mutations in known oncogenes are assigned as destabilizing, more usually 
implying loss of function, rather than gain. We examine these more closely, in order to better 
understand this unexpected finding. Six of the destabilizing mutations are in KRAS. Very 
extensive studies of KRAS and the closely related (89% sequence identity) HRAS have 
established that when GTP is bound (the „ON‟ state), these proteins act as a signal for cell 
growth, through interaction with effector proteins. RAS is converted from the „OFF‟ GDP 
bound state to the ON state as an indirect result of the presence of extracellular growth 
factors, primarily through the binding of guanine nucleotide exchange factors (GEFs). 




accelerated by binding of GTPase activating proteins (GAPs).
125
 It has long been recognized 




Four of the KRAS mutations in the survey data occur at the most common RAS oncogenic 
site, G12. All four are classified as high impact by the Profile method. There are a number of 
GDP/GTP, GEF and GAP complexes, as well as mutant structures, available for HRAS. Our 
stability analysis pipeline selected the only available KRAS structure, which is in the ON 
state, with GTP analog bound (PDB 2pmx). Three G12 mutants (G12V, G12S and G12D) 
produce destabilization assignments as a consequence of clashes with the side chain of Q61, 
which lies in the flexible switch II region. In other HRAS structures examined (GTP bound, 
PDB 6q21, and GDP bound PDB 4q21) these clashes are avoided by an alternative position 
of the Q61 side chain. However, this latter Q61 orientation would reduce the rate of GTP 
hydrolysis, extending the half life of the ON state, and further, the Q61 alternative 
conformation is incompatible with the structure of a rasGAP/HRAS (PDB 1wq1) complex so 
that the mutants will also extend the ON state by reduction of GAP binding. Thus, these 
mutants appear to shift KRAS towards a more populated ON state by destabilizing 
conformations and complexes that promote GTP hydrolysis. The reverse reaction, 
replacement of GDP by GTP, is primarily through GEF facilitated dissociation of GDP, and 
so is not affected by the Q61 alternative conformation (HRAS/GEF complex structure PDB 
1xd2). In addition to this probable oncogenic mechanism, non-glycine residues at position 12 
clash with the main chain of residue R789 of bound rasGAP, destabilizing the complex 
(illustrated by the fourth G12 mutant in the survey data, G12A, Figure 2.3e). R789 is directly 
involved in catalysis in the complex (modeled HRAS/rasGAP structure PDB 1wq1),
127
 so 
may be particularly sensitive to clashes. Other explanations for the action of G12 mutants, 






A146T, K117N and G13D in KRAS all appear to weaken GTP/GDP binding, and are also 
destabilizing to different degrees. For G13D, in the absence of any adaptive conformational 
change, the apparent effect on stability is dramatic, with backbone strain and serious steric 
clashes, all involving well ordered residues in all examined KRAS or HRAS structures. The 
magnitude of destabilization by K117N is likely milder, with a moderate loss of hydrophobic 
burial. A146T has a low confidence prediction of destabilization. The consistent 
destabilization signal for these three mutants, and especially the major structure disruption for 
G13D, suggest that an as yet unidentified conformational changes play a role in the effect on 
GTP exchange rate. An experimental study of related mutants including A146V and K117N 









Figure 2.3. Example modes of action for some high impact mutations in known cancer 
genes. 
(a) Loss of protein stability through a steric clash. Replacement of valine 157 (yellow) with 
phenylalanine (purple) in the tumor suppressor TP53 introduces a severe steric clash (red 
discs) with neighboring residues, destabilizing the tertiary structure. (mutation modeled with 
human TP53 structure PDB 1tsr)  
(b) Loss of protein stability through disruption of an electrostatic interaction. Aspartic acid 
300 (yellow) changed to valine (purple) in the tumor suppressor SMAD2. The electrostatic 
interaction between D300 and R310 (red dashed lines) is broken and there are steric clashes 
between one of the valine methyl groups and surrounding residues (red discs). Both effects 
destabilize the tertiary structure. The blue chain represents a second subunit of the functional 
complex. (modeled with human SMAD2 structure PDB 1khx)  
(c) Loss of protein stability through disruption of a subunit interface. Arginine 361 (yellow) 
of the tumor suppressor SMAD4 forms an inter-chain salt-bridge (red dashed lines) with a 
conserved aspartic acid (green) of another subunit in the human homo-trimeric (PDB 1dd1) 
or hetero-trimeric complexes with SMAD2 or SMAD3 (PDB code 1u7f SMAD3/SMAD4; 
1u7v for SMAD2/SMAD4). The ARGHIS (purple) substitution destabilizes the interface. 
Many tumorigenic mutations have been mapped to this conserved interface.
131
 
(d) Loss of protein function through disruption of a ligand interaction. Arginine 248 (yellow) 
in TP53 interacts with a DNA backbone phosphate in the protein-DNA complex (DNA 
shown in space filling). Substitution of tryptophan disrupts DNA binding electrostatically and 
sterically. (modeled with human TP53 structure PDB 1tsr) 
(e) Gain of protein function through disruption of a protein-protein interaction. Glycine 12 is 
located near the GTP/GDP binding site and at the interface between the oncogene KRAS 
(green) and GTPase Activating Protein (rasGAP, in blue). Substitution of alanine (purple) 
produces a steric clash (red disc) with the carbonyl group of R789 of rasGAP (blue), reducing 
the strength of the complex, hence reducing the rate of GTP hydrolysis, and thus increasing 
the concentration of GTP bound „ON‟ state KRAS. Dot spheres represent the GTP analog 
GDP-AF3. (modeled with human HRAS/rasGAP complex structure PDB 1wq1) 











 R40H, in another RAS family protein, RAB5C, is also close to the active site. It is located 
just upstream of the dynamic switch region I which forms part of the binding pocket for the 
nucleotide. This mutation likely destabilizes the switch region rather than the whole protein. 
Disordering of the switch region as a result of alternative splicing, with concomitant up-




The last destabilizing oncogenic mutation, G424A in NUP214 (nucleoporin 214kDa), lies in 
a linker region between two domains, suggesting that the backbone strain created by the 
mutant may be easily relieved, reflected in a low confidence assignment. The oncogenic 
mechanism is not clear. 
Thus, a number of the oncogenic mutations appear to be destabilizing when only a single 
conformation of these often allosteric proteins is considered. Destabilization is relieved by 
conformational changes that alter the activation state of the protein. The impact analysis 
successfully identifies destabilization of a conformational state in these highly regulated 
proteins, but knowledge of all relevant conformational states is needed to fully interpret the 
results. 
 
Subsection 4. Impact Analysis of all Somatic Missense Mutations 
Figure 2.4 summarizes the impact analysis for all somatic missense mutations. Both the 
Profile and Stability methods classify approximately 50% of all mutations as high impact 
(Figure 2.4a). Very similar values are found for the subset of highest confidence impact 
assignments (labeled as „HC‟). The fractions found for just the initial Discovery screen 
mutations are also similar (Figure 2.4b), as are Profile values for mutations in Validated 




analysis with the sequence based SIFT method
27
 is similar, while for LS-SNP,
22
 a method 
combining sequence and structure information, values are consistently somewhat higher. For 
all methods, correction for the false positive and false negative rates increases the high impact 
fraction by between 6 and 9%. There is no significant difference between values for the two 
cancer types (Figure 2.4d and 2.4e). The top ranked genes from the survey CAN gene set 
have similar impact levels (Figure 2.4f). All these values are significantly lower than those 
found in the known cancer genes (χ
2
 test, P < 0.001). The results suggest that rather more 
than half of somatic missense mutations in these cancer genomes have a high impact on in 
vivo protein activity, and the primary molecular mechanism is destabilization of protein 






Figure 2.4. Fraction of all somatic missense mutations with high impact using four 
impact analysis methods. Solid bars show the high impact fractions, and open bars show the 
additional fraction after correction for false positive and false negative rates. HC denotes high 
confidence classifications.  
(a) All missense mutations for both types of cancer. 
(b) Missense mutations identified in the Discovery screen. 
(c) Those in the Validated gene set.  
(d) All missense mutations in breast cancer samples. 
(e) All mutations in colorectal cancer samples. 
(f) All missense mutations in the top ranked 98 genes in the survey CAN set.  
The fraction of high impact mutations is similar in all sets, and much lower than in the known 







In contrast to this, application of the Profile and Stability methods to validated germ line 
SNPs (dbSNP
134
 v128 data) in the same set of genes finds that only about 30% (after 
correction for error rates) are high impact. Cancer mutation impact levels may also be 
compared with that expected if there were no selection. To estimate that quantity, we 
systematically introduced every possible missense single base substitution for all residues 
(i.e. up to three amino acid substitutions per site) in these genes (except the termini). 56% 
(67% after correction) are high impact using the Profile method. As discussed later, there are 
a number of causes for the large fraction of high impact mutations in the cancer data. 
Many samples used in the survey were from cultured cell lines or xenografts, not micro-
dissected tumor tissues. It has been observed that some mutations in these types of cultured 
samples have undergone adaptation under in vitro culture conditions, rather than being 
involved in in vivo tumor progression.
135
 To investigate this effect, we also considered only 
those missense mutations in primary tumor samples obtained by micro-dissection. There are 
151 distinct missense mutations in 29 such tissues, all from the Validation screen of breast 
cancers. As shown in Figure 2.5 and Supplementary Table S2.4, the high impact fraction 
estimate here is 46%, not significantly lower than found for all samples. Thus, in vitro 






Figure 2.5. Fraction of high impact mutations in micro-dissected primary tumors, using 
four impact analysis methods. The solid bars show the high impact fractions, and the open 
bars show the additional fraction after correction for false positive and negative rates. The 
level of high impact mutations is similar to that in all tumor samples, indicating there is no 








Figure 2.6. Impact analysis of missense somatic mutations in breast (1-11) and colon 
(12-22) cancer samples.  
Red: High impact mutations; Blue: low impact mutations. Impact assigned with the Profile 
method. The number of mutations varies widely, while the high impact fraction is 







We also considered the ratio of mutations with high impact in each cancer individual (Figure 
2.6). In the Discovery screen, there were 11 breast and 11 colorectal cancers sequenced, with 
between 29 to 157 missense mutations per cancer (average values are 66 and 82 for colorectal 
and breast cancer respectively). Most of these can be assessed by the Profile method. The 
fraction of high impact mutations is approximately constant with average values of 0.49±0.06 
and 0.52±0.06 for breast and colorectal cancers respectively. The roughly constant fraction of 
high impact mutations, independent of the total number, suggests that only a small percentage 
of these are actually drivers. 
In contrast to the high fraction of homozygous mutations in known cancer genes, only 11% 
and 9% of the other missense mutations are homozygous for mutations in the Discovery and 
Validated genes respectively. The homozygous level for indels is also lower, at 19%. For the 
destabilizing mutations (13% and 11% respectively), and high impact mutations from the 
Profile method (10% and 6%), the fractions are similar. The rate for synonymous mutations is 
also similar at 15%. Contrasting these values with those found for mutations in known cancer 
genes and the similarity between the values for all mutations and high impact ones suggests 
that only a small fraction are drivers.  
 
Subsection 5. Molecular mechanisms of potential new driver mutations 
There are a total of 256 predicted high impact missense mutations in 187 validated genes that 
are not in any of the three cancer lists considered, and this set is likely the most enriched for 
new driver mutations. Detailed structural information is necessary to investigate the 
molecular mechanisms by which new potential drivers act, and 34 mutations in 29 genes have 
sufficient structural information for further analysis. Supplementary Table S2.6 provides a list 




relevance to cancer of the corresponding genes ranges from no known connection, for 
example, ribose-phosphate pyrophosphokinase 1 (PRPS1), to already well studied and clear, 
for example, the extra cellular protease ADAM12. As found for the core cancer gene sets, the 
most striking feature is the high level of destabilization of protein structure: 21 of the 34 
mutations appear to act through this mechanism.  
As with the mutations in well established cancer genes, those causing loss of function through 
destabilization (and therefore in presumed tumor suppressor genes) are the most 
straightforward to interpret. Examples from three proteins illustrate the range of molecular 
mechanisms and relationship to progression of the disease. The first case is two destabilizing 
mutants in xanthine dehydrogenase (XDH). The homozygous R791G mutation is in a subunit 
interface (Figure 2.7a), and results in a weakened subunit interaction. The heterozygous 
substitution L763F leads to a destabilizing steric clash in the protein interior (picture not 
shown). This gene is involved in free radical Induced apoptosis,
136
 thus loss of function is 
consistent with delayed cell death. It is also involved in reductive activation of 
chemotherapeutic agents.
137
 A second, well studied, case is the heterozygous destabilizing 
D301H mutant in ADAM12 (Figure 2.7b), which acts through removal of one of the side 
chains interacting with a bound calcium atom in the wild type protein. This mutant has been 
shown to lead to loss of transport to the cell surface, probably because of misfolding in the 
endoplasmic reticulum (ER).
138
 The protein is a multimer, and it is likely that mixed mutant 
and wild type oligomers are rejected by the ER, causing this mutant to act in a dominant 
manner. ADAM12 is an extra-cellular protease involved in digestion of some tumor 
factors,
138
 also consistent with a tumor suppressor role. Conversely, it is over-expressed in 
some tumors,
139; 140
 suggesting that in some circumstances it may have an oncogenic role. 
Finally, the homozygous R528H substitution in TGFBR2 (transforming growth factor beta 
receptor II) causes a serious steric clash, and a loss of a salt bridge, likely leading to a very 




tumor suppressor SMAD2, so facilitating the latter‟s transport to the nucleus, where it 
regulates transcription. This gene has been suggested as a putative tumor suppressor by 
several studies (OMIM 190182).
141
 
A second class of mutants causes loss of molecular function through mechanisms other than 
destabilization. An example is heterozygous R704Q in the kinase domain of EPHB6 (ephrin 
receptor B6), a mutation that disrupts an electrostatic interaction with a phosphate group of 
ATP, implying loss of catalytic function (Figure 2.7d). Loss or decreased activity of this 
protein is related to tumor progression and invasiveness.
142
  A second example in this 
category exhibits a combination of loss of molecular function and destabilization. The 
heterozygous mutation E507D in GALNT5 (UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-acetylgalactosaminyltransferase 5) weakens the electrostatic 
interaction with a nearby arginine (Figure 2.7e). The glutamic acid at position 507 also forms 
an electrostatic interaction with a hydroxyl group of UDP. This mutation has been found to 
have 0% in vitro specific enzymatic activity.
143
 GALNT5 is a member of the O-linked N-
acetylglucosaminyl (O-GlcNAc) transferase gene family, which catalyze glycosylation of 
serine and threonine residues. Several known cancer genes have been reported as O-GlcNAc 
glycosylated such as HIC1, TP53, c-MYC.
144
 
The third class of mutations increases molecular activity, and therefore acts in an oncogenic 
manner. These generally cannot be classified unambiguously with current computational 
methods, and require knowledge of all relevant conformational states. An example is the 
heterozygous D806N mutation in EPHA3 (Ephrin-A class receptor tyrosine kinase). The 
mutation is in the kinase domain, close to the activation loop (Figure 2.7f) and likely results 
in increased kinase activity by destabilizing the inactive conformation. Over-expression has 
been reported for this gene in different types and stages of tumor development.
145; 146
 Two 
other large proteins related to vesicle trafficking (LRBA and LYST) may be unregulated by 




mechanism is unclear. A grove between the BEACH and PH domains is believed to be 
involved in an unknown intermolecular interaction, and loss of this binding site through 
domain destabilization may result in change of location of the proteins, contributing to cancer 








Figure 2.7. Examples of potential driver mutations in the Validation set. 
(a) A destabilizing mutation in XDH (xanthine dehydrogenase), R791G: Substitution with 
glycine (purple) removes the electrostatic interactions (red dashed lines) formed by the wild-
type arginines (yellow, one in each subunit) with glutamic acids on the neighboring subunits 
(subunit backbones colored in green and blue). The catalytic function of XDH is important in 
free radical induced apoptosis and activation of chemotherapeutic agents. The destabilizing 
effect of R791G and another mutation L763F (picture not shown) down-regulate XDH 
activity and hence act as tumor suppressors. (modeled with human XDH structure PDB 2e1q) 
(b) D301H in ADAM12 (metalloprotease disintegrin 12): The wild type aspartic acid, co-
ordinated to a calcium ion (magenta sphere), is replaced with a histidine (purple). The larger 
side chain reduces calcium binding affinity and introduces steric clashes (red discs), 
destabilizing the structure, consistent with a tumor suppressor role for the protein. Reduced in 
vivo proteolytic activity of this mutant results in reduced tumor growth inhibition.
138
 
(modeled with human ADAM12 structure PDB 1r55)  
(c) R528H in TGFBR2 (transforming growth factor beta receptor II): The arginine (yellow) – 
aspartic acid saltbridge is abolished by the histidine (purple) substitution and steric clashes 
(red disks) are introduced. TGFBR2 phosphorylates SMAD2, a tumor suppressor. The 
phosphorylated form of the latter enters nucleus and forms a transcription repressor complex 
that regulates cell growth related processes. (modeled with human activin receptor type 2B 
(ACVR2B) structure PDB 2qlu) 
(d) R704Q in EPHB6 (ephrin receptor B6): The mutant glutamine (purple) disrupts the 
catalytic interaction of the wild-type arginine (yellow) with GTP. Down-regulated expression 
of EPHB6 has been observed in melanoma,
142
 and loss of catalytic function would also result 
in reduced in vivo activity. (EPHB6 modeled with mouse homolog EPHB2 structure PDB 
1jpa; GTP analog, dot spheres with label „ANP‟, and magnesium, red sphere with label „Mg‟, 
from human EPHA3 structure PDB 2qo7) 
(e) E507D in GALNT5 (UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 5): The wild-type glutamic acid (yellow) interacts with both 
UDP and a neighboring arginine. Substituting a shorter side chain (aspartic acid, purple) 
results in loss of the electrostatic interaction with the neighboring arginine and the NGA-UDP 
ligand (dot spheres; „NGA‟: N-acetyl-D-galactosamine). It is likely that reduced GALNT5 
activity acts as a driver, since several known cancer genes are regulated by glycosylation
144
 
and loss-of-function mutations in the homolog GALNT10 are observed in colon cancer
143
. 
(modeled with human homolog GALNT10 structure PDB 2d7i; Manganese ion, yellow 
sphere with label „Mn‟) 
(f) D806N in EPHA3 (Ephrin-A class receptor tyrosine kinase): Substitution of aspartic acid 
(yellow) by asparagine (purple) results in loss of a charge-dipole interaction with a backbone 
hydroxyl group. This change likely impacts the conformation of the nearby activation loop 
(disordered, black dashed line). The probable result is a gain of function since over-
expression of this protein has been found in multiple tumors.
145; 146
 (modeled with human 
EPHA3 structure PDB 2qod. Magnesium (Mg, red sphere) and ANP (GTP analog, dot 
spheres) are modeled by aligning with human EPHA3 structure PDB 2qo9). 










Section 4 Discussion 
In this study, we have used two computational methods
32; 33
 to determine the prevalence of 
high molecular impact missense mutations in a set of cancer sample exon sequences,
48; 49
 and 
considered their role as potential drivers. The primary conclusions are as follows: 
1. Missense mutations in known cancer genes have a high impact on in vivo protein function. 
The computational methods used are designed to detect relatively high levels of impact on 
molecular function, such as are typically found in monogenic disease.
33
 For mutations 
affecting stability, typically a change in the free energy difference between the folded and 
unfolded protein states of greater than 2 Kcal/mol is required to produce a high impact 
assignment, likely corresponding to a multi-fold reduction of in vivo activity.
33
 It is expected 
that the Profile method has a similar sensitivity. It is not yet clear what the relative roles of 
high and low impact mutations are in complex polygenic diseases, including cancer. Analysis 
of the survey somatic missense mutations lying in known cancer related genes allows this 
question to be addressed. For tumor suppressors, both methods find a large fraction of 
mutations to be of high impact (approaching 100%). For oncogenes, the fraction is a little 
lower, at around 80%. The two other missense mutation analysis methods
22; 27
 applied to the 
data produced similar results.
49
 Thus, although the amount of data is limited, the analysis 
strongly suggests that most of the apparent drivers in known cancer genes have a high impact 
at the molecular level and will be detectable using these methods. 
2. The full set of somatic mutations has a lower fraction of high molecular Impact missense 
mutations than found in the known cancer genes. In contrast to the large fraction of high 
impact mutations found in the known cancer genes, the fraction found in the full set of 
mutations in the cancer specimens is substantially lower. In the initial Discovery set (included 
any mutation found), about 60% mutations are assessed as high impact. In the Validation set, 




mutations in these samples are of low molecular impact, and likely passengers. Some fraction 
of the remainder are drivers.  
3. The fraction of high impact somatic mutations is substantially higher than for germ line 
SNPs. Application of the Profile method to the known germ line non-synonymous SNPs in 
the Discovery set of genes finds 30% to be of high molecular impact, about half of the level 
found for the somatic missense mutations, and consistent with the level found for SNPs in all 
genes.
32
 Systematically introducing every possible missense single base mutation into this set 
of genes yields an estimated 67% high molecular impact, not much higher than the 60% 
found for the somatic mutations. Thus, high impact somatic mutations are almost as common 
as would be expected if there were no selection against them. The observed level of high 
impact reflects the interplay of several factors. First, unlike with germ line SNPs, it is 
expected that a significant fraction of mutations are drivers of disease, and selected for in the 
tumor cell lines. Second, as with germ line SNPs, some fraction will be effectively buffered 
from a deleterious impact on cell function by higher levels of system organization. Third, 
some may have a deleterious effect on processes not relevant to a cell culture, such as genes 
involved in development, and so are not selected against. Fourth, some may be deleterious to 
the cell line, but not yet been selected out, in a manner analogous to the presence of 
deleterious germ line SNPs that are expected to be eventually eliminated.
24
 The dynamics of 
selection in these cells will be very different from that for germ line variants, and new 
deleterious mutations may be created at a high rate, particularly in view of the high incidence 
of damaged DNA repair mechanisms. 
4. Destabilization of protein three-dimensional structure plays a major role in the molecular 
mechanisms of cancer related somatic mutations. As is the case with germ line SNPs,
32
 we 
find that a large fraction of all high impact mutations affect protein function in a manner 
consistent with the destabilization of the folded state of the protein concerned. Of all somatic 




consistent with a destabilized structure (detail in Supplementary Table S2.3). In the NCBI 
CAN gene set, 21 out of 24 high impact mutations in tumor suppressors are categorized as 
destabilizing, and 7 out of the 11 high impact mutations in oncogenes are so categorized. 
For tumor suppressors, destabilization is related to a loss of in vivo function, consistent with 
the loss of suppression activity, and so contributing to disease, and the findings are consistent 
with those for monogenic disease mutations
33
 and high impact germ line SNPs
32; 123
, a large 
fraction of which are expected to result in lower in vivo molecular function. For oncogenes, a 
gain of molecular function is normally expected, and at first glance, that is not consistent with 
the observed loss of stability. Closer inspection shows that for the cases examined, the 
destabilization assignments are in fact consistent with gain of function, through two 
mechanisms. One mechanism is destabilization of the less active form of allosteric proteins, 
and the second is destabilization of conformational states or protein complexes that promote 
the transition from the active to the less active form, such as catalysis of GTP hydrolysis in 
KRAS, both driving an increase in population of the more active state. More sophisticated 
computational methods are needed to fully explore these mechanisms. 
5. Only a fraction of high impact cancer mutations are drivers. The finding that a very high 
fraction of mutations in established cancer genes (presumed drivers) have a high impact on 
molecular function, but only an estimated 50 to 60% of all survey mutations are high impact 
sets an upper limit for the fraction of drivers. Also, there is very little significant enrichment 
of high impact mutations in the Validated versus the Discovery set genes, as would be 
expected if most mutations in the Validated set were drivers. As noted earlier, the presence of 
high impact mutations that are not drivers is not surprising – high impact mutations may be 
buffered at the cellular level and so not deleterious to fitness, may be in genes not critical at 
the cellular level, or may reflect incomplete selection against deleterious alleles. Additional 
information from other signals is needed to determine which subset of the high impact 




cancer mutations in known cancer genes..
63
 That study concluded the fraction of drivers in a 
set of glioblastoma samples is only 8%. 
6. Structure analysis can provide a detailed view of driver mutation mechanism, assisting in 
assessment of potential new therapeutic targets. In those cases where either an experimental 
structure or a high quality structure model is available, it is often (though not always) 
possible to identify the mode of action of a missense mutant at the molecular level, and so 
assess whether a therapeutic intervention aimed at that target might be successful. Generally, 
tumor suppressor loss of function (for example, the classical loss of binding to DNA for 
TP53, illustrated in Figure 2.3d) is difficult to directly reverse. The major therapeutic 
opportunity revealed by the present analysis is that reduction in thermodynamic stability 
plays a very major role for drivers in tumor suppressors, compared to effects on binding and 
molecular function. There are cases of restoration of thermodynamic stability for monogenic 
disease genes,
148
 and similar strategies should be applicable for appropriate tumor 
suppressors. For oncogenes, conventional blocking of activity is well established (for 
example, for HER2
149
). The observation of a role for allosteric state selection through 
destabilization of the less active conformation suggests an additional strategy of re-stabilizing 
the „OFF‟ conformation. 
 
Section 5 Materials and Methods 
Subsection 1. Cancer Somatic Mutation Dataset 
Somatic missense mutations were obtained from the wood et al.
49
 data (the supplementary 
Table S2.3, available on the journal website). 1963 distinct missense mutations were 
extracted, excluding 3 mutations at N termini. The corresponding protein sequences were 




„NM‟ mRNA identifiers. Tumor derivation (primary tumor or metastasis) and sample type 
(cell line, xenograft or micro-dissected tumor tissue) were taken from the supplementary table 
S2.2 in Ref. 1. Three of the 37 colorectal cancer samples are derived from primary colorectal 
tumors, and the rest are from liver and lymph node metastasis. All colorectal cancer samples 
are from cell lines or xenografts. Of the 48 breast cancer samples, one is from lymph node, 
and the rest from primary tumors, of which 36 are from micro-dissection and the rest from 
cell lines. 
Subsection 2. Sequence profile and structure stability methods for mutation impact 
analysis 
Details of the methodology have been previously described.
32; 33 
Here we provide a summary. 
The structure stability method identifies those amino acid substitutions that significantly 
destabilize the folded structure of a protein molecule. A set of 15 parameters is used to 
characterize structural effects, such as reduction in hydrophobic area, overpacking, backbone 
strain, and loss of electrostatic interactions. A support vector machine (SVM) was trained on 
a set of mutations causative of monogenic disease (extracted from the Human Gene Mutation 
Database
6
), and a control set of amino acid differences between human and closely related 
mammals, assumed to be non-disease causing. In jack-knifed testing, the method identifies 
74% of disease mutations as affecting protein stability. Note that a high false negative rate is 
expected, since the method only considers stability effects, not other types of impact in 
function. The false positive rate is 17% when all mutations are included, and 11% for higher 
confidence assignments (those with an SVM score ≤ -0.5). Use of the method to evaluate a 
set of in vitro mutagenesis data with the SVM established that the majority of monogenic 
disease mutations affect protein stability by 1 to 3 Kcal/mol. (See Ref. 19 for a full 
description.) A recent limited scale experimental study of all common non-synonymous 








The Profile method makes use of the extent of family sequence conservation and types of 
amino acids observed at a residue position.
32
 The more restricted the amino acid, the more 
likely that a different or unusual residue at that position will impact protein function. A SVM 
is also used to identify high impact substitutions in this model, using the same disease and 
control datasets as for the Stability method. In jack-knifed testing, the method identifies 80% 
of disease mutations with a false positive rate of 10%. (For high confidence assignments, 
false negative and false positive rates are 16 and 6% respectively.) The slightly higher level 
of assignment of high impact for this method is expected, since it can detect all types of 
protein-level high impact effects, while the structure based model is restricted to stability. 
This method has the advantage that it does not require knowledge of structure and so can be 
applied to a larger fraction of SNPs. It has the disadvantage that it provides no direct insight 
into the nature of the impact on protein function. 
For both methods the SVM returns a score related to the confidence of the impact 
assignment. A negative score indicates high molecular impact, while a positive score as low 
impact. High Confidence (HC) classifications refer to those SVM classifications with |SVM 
score| ≥ 0.5. 
 
Subsection 3. Impact analysis using the SIFT and LS-SNP methods 




 are taken from 
the supplementary table S2.3 of Ref. 2. SIFT generally considers a mutation with an impact 
score smaller than 0.05 as deleterious to protein function. LS-SNP reports a determinant 





Subsection 4. Correction of high impact fractions for false positive and false rates 




                              
where Hobs is the observed high impact fraction and Htrue is the corrected value. For the Profile 
method Hfp=9%, Hfn=20%; Profile HC: 6% and 16%; for the Stability method: 17% and 26%; 
Stability HC: 12% and 21%. For SIFT: Hfp=31% and Hfn=20%;
34




Subsection 5. Cancer Gene Sets 
The four sets of genes implicated in cancer used in the study are: 
1. The „NCBI CAN‟ gene list, produced by searching for “oncogene” or “tumor suppressor” 
in the gene/protein full name field of the NCBI Gene database (1/2008), and consists of 230 
oncogenes and 63 tumor suppressors. Two additional well known tumor suppressors, 
SMAD2 and SMAD4, were added. 
2. The Sanger Census cancer gene list is a collection of 362 genes found to be modified in 
somatic or germ line in several kinds of tumors (download from 
http://www.sanger.ac.uk/genetics/CGP/Census/ as of 2007-02-13).
38
  
3. Fsearch is an in-house literature mining tool, similar to that described previously.
32
 We 
began with the oncogene and tumor suppressor genes in the „NCBI CAN‟ set. All PubMed 
abstracts containing these gene names were collected and a word and phrase frequency 
profile constructed for each. These profiles were then compared with each member of the full 
set of precompiled gene profiles. The top 200 hits from each list were selected and merged, 




4. The survey CAN gene set was obtained from Supplementary Tables S2.4A and S2.4B in 
the sequencing study.
49
 There are 140 genes for each tumor type, with a total of 273 distinct 
genes. The „top ranked‟ set used in Figure 2.4f is a combination of the top 50 ranked genes 
from each tumor type, giving a total of 98 distinct genes. 
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Chapter 3: Protein Stability and In Vivo Concentration of 
Missense Mutations in Phenylalanine Hydroxylase 
 
Section 1 Abstract 
A previous computational analysis of missense mutations linked to monogenic 
disease found a high proportion of missense mutations affect protein stability, rather 
than other aspects of protein structure and function. The purpose of the present study 
is to relate the presence of such stability damaging missense mutations to the levels of 
a particular protein present under „in vivo‟ like conditions, and to test the reliability of 
the computational methods. Experimental data on a set of missense mutations of the 
enzyme phenylalanine hydroxylase (PAH) associated with the monogenic disease 
phenylketonuria (PKU) have been compared with the expected in vivo impact on 
protein function, obtained using SNPs3D, an in silico analysis package. A high 
proportion of the PAH mutations are predicted to be destabilizing. The overall 
agreement between predicted stability impact and experimental evidence for lower 
protein levels is in accordance with the estimated error rates of the methods. For these 
mutations, destabilization of protein three dimensional structure is the major 
molecular mechanism leading to PKU, and results in a substantial reduction of in vivo 
PAH protein concentration. The results support the view that destabilization is the 





Section 2 Introduction 
In a previous study of monogenic disease-associated missense mutations, we found 
that many are predicted to reduce protein stability.
33; 69
 These results are surprising 
since the associated reduction in stability of approximately 1~3 Kcal/mol would not 
be expected to affect protein function significantly in vitro, given a typical free 
energy of stabilization of the folded state of the order of 10 Kcal/mol.
150
 There are 
few experimental data on the relationship between disease missense mutations and 
protein properties under in vivo like conditions. One excellent source of information 
is for missense mutations found in the human hepatic enzyme phenylalanine 
hydroxylase (PAH) (EC 1.14.16.1), associated with phenylketonuria (PKU, OMIM 
261600).   
 
PKU is an autosomal recessive inherited disorder and the most common inborn error 
of amino acid metabolism, with average birth incidence of about 1 in 10,000 among 
European descent and Asian populations.
151; 152; 153; 154
 The conversion of dietary L-
Phe to L-Tyr is catalyzed by PAH. The enzyme is the major means of degrading 
dietary L-Phe and the rate-limiting step controlling the catabolism of L-Phe.
155
 
Deficiency in PAH enzyme activity results in elevated phenylalanine concentration in 
the body and abnormally high levels of metabolites from phenylalanine by other 
metabolic pathways. L-Tyr is the substrate for the biosynthesis of the thyroid 
hormone thyroxine, the neurotransmitter dopamine, the adrenal hormones, and the 
pigment molecule melanin.
156
 Lack of L-Tyr and excess of L-Phe, which acts as an 




retardation and decreased pigmentation. Clinically, patients are assigned to one of 
four phenotype categories based on a continuum of blood phenylalanine level and 
dietary phenylalanine tolerance. The most severe is “classic PKU”, followed by 
“moderate PKU”, “mild PKU”, and the least severe, “mild 
hyperphenylalaninemia”(MHP) (summaried in Guldberg et al. 
157
). More than 500 
naturally occurring DNA mutations which affect the function of human PAH in vivo 
have been identified and archived in the PAH Mutation Analysis Consortium 
database (PAHdb 
158
, www.pahdb.mcgill.ca). About sixty percent of these are 
missense mutations arising from single base changes.
159
 Homozygous or compound 
heterozygous genotypes of these missense mutations generally result in PKU. 
 The effects of a subset of PKU-associated PAH missense mutations have been 
studied in cultured cells and cell lysate extract, representing in vivo like conditions. 
Data on these are available through the PAHdb.
158
 In these experiments, the mutant 
and wild-type PAH cDNA constructs were transiently transfected and expressed in 
the host cells. The total enzyme activity, the PAH immune-reactive protein level, and 
sometimes the mRNA level were measured. These data provide a basis for testing the 
relationship between destabilization of protein structure and protein in vivo activity. 
Crystal structures of PAH have shown that the human enzyme is a homo-tetramer.
160
 
Each chain has an N-terminal regulatory domain (residues 1-110), a catalytic domain 
containing an iron atom (residues 111-410) and a tetramerization domain (residues 
411-452) (Fig. 1). The substrate L-Phe and cofactor tetrahydrobiopterin (BH4) both 
have binding sites in the catalytic domain. The availability of the crystal structures of 




structure and molecular function (see Methods). An extensive review of the location 
of disease-associated missense mutations in the structure has been published.
161
 Here 
we focus on relating predictions of lower protein stability to protein characteristics 
under in vivo conditions, and testing the computational assignments against the 
experimental data. 
 
A number of computational methods have been developed to identify which missense 
base substitutions have a high impact on in vivo protein function. These methods are 
based sequence conservation patterns,
27; 32
 features of protein three dimensional 
structure,
24; 33
 or a combination of both.
21; 22; 23; 121
 A variety of machine learning 
21; 22; 
32; 33; 121
 and statistical 
23; 27
 approaches are employed together with appropriate 
training data to utilize the sequence and structure features. We have developed a 
method that identifies substantial changes in the thermodynamic stability of a protein 
structure, based on the detailed structural environment of a mutation.
33
 The method 
uses a Support Vector Machine (SVM
122
), trained on data for mutations that are 
considered to cause monogenic disease, taken from the Human Gene Mutation 
database (HGMD 
6
, www.hgmd.cf.ac.uk, as of 02/09/2002, (later versions of the 
database include many non-causative mutations)) and a control set of amino acid 
differences between corresponding mouse and human orthologs. Each mutation is 
characterized by 15 features, including perturbation of electrostatic factors, packing 
efficiency, steric clashes, breakage of disulfide bonds, polypeptide backbone strain, 
and the relative extent of local structural rigidity. Full details of the method and its 
benchmarking have been previously published.
33




assigns 74% of the HGMD monogenic disease mutations as destabilizing. 
Comparison with experimental data for a set of site directed mutations in bacterial 
and phage proteins established that destabilizing monogenic disease mutations 
typically reduce the free energy difference between the folded and unfolded state of a 
protein by 2 to 3 Kcal/mol.
33
 . We have also developed a support vector machine 
utilizing sequence conservation features to detect those mutations that have a high 
impact on any aspect of the protein function, not just destabilization.
32
 These two 
support vector machines are implemented in a web interface and database 
infrastructure, SNPs3D (www.SNPs3D.org), which contains an analysis of human 
SNPs using the two methods. Blind testing against experimental data on a small set of 
common non-synonymous SNPs produced a high level of agreement between 
predicted destabilization and lower melting temperature for the variant containing 
proteins.
123
 The experimental properties of mutations in monogenic disease proteins 
such as PAH provide the most direct test of the earlier finding that destabilization of 
protein structure plays a major role in monogenic disease. 
Destabilization of protein structure presumably reduces in vivo protein abundance, 
either through unsuccessful protein folding, or increased chaperone scavenging of 
transiently unfolded molecules. Destabilization alone is not expected to alter enzyme 
specific activity, but a destabilizing mutation may additionally impact molecular 
function, in ways that may be identified from the structural context. For example, the 
mutation lies in the ligand binding site. Other mutations may only impact molecular 
function, and not stability. On this basis, there are five categories of prediction from 




Category 1: Where a mutation is assigned as destabilizing, and is not directly 
involved in molecular function, we expect low in vivo protein abundance, and wild-
type specific activity.  
Category 2: Where a mutation is assigned as destabilizing, and there is structural 
evidence of an impact on molecular function as well, we expect low in vivo protein 
abundance, and low specific activity.  
Category 3: Where a mutation is not assigned as destabilizing, but is assigned as 
affecting molecular function, we expect wild-type protein abundance, low specific 
activity, and evidence of involvement in function from the structure.  
Category 4: Where a mutation is assigned as not destabilizing and as not affecting 
any aspect of function, we expect wild-type protein abundance, wild-type specific 
activity and a mild disease classification. Below, we consider each of these prediction 
categories and the extent to which these expectations are met.   
 
Section 3 Results 
Subsection 1. Impact analysis of missense mutations on PAH function and protein 
stability 
46 distinct human PAH missense mutations with suitable experimental data were selected 
from the PAHdb database (version of January 2010). These had all been expressed in a 
mammalian COS or A293 cell expression system, with total enzyme activity and protein level 
measured for mutants and wild-type under the same conditions. In most cases, mRNA levels 
are also available. There are multiple experimental results available for 16 of the mutations, 
providing an indication of experimental precision. Fig. 3.1 shows the distribution of the 




analyze each mutant. The results, together with the experimental data, are shown in Table 3.1. 
Of the 46 mutations, 35 (76%) are assigned as high impact on protein stability. The sequence 
conservation method assigns 42 as high impact from all causes. Only two mutations show no 
impact by either method. Eleven of the mutations are within 6.5 Å of substrate, cofactor, or 






Figure 3.1. Structure model of phenylalanine hydroxylase used for mutation analysis. 
Domains are: regulatory (yellow); catalytic (green); tetramerization (blue). The 39 residues 
with mutations discussed in this study are in red. The Fe (++) ion is magenta, and a substrate 
analog, Beta(2-thienyl) alanine (TIH) and cofactor Tetrahydrobiopterin (BH4) are shown 







Table 3.1. Functional and stability impact analysis results of 46 PAH missense 
mutations together with experimental measurements of activity and protein level, and 
clinical PKU classification. A negative score for the stability method indicates an expected 
impact in protein stability. A negative score for the profile method indicates an expected 
impact on protein function in vivo from any cause, including stability. The absolute value of a 
score shows the confidence for a particular assignment. Benchmarking (Ref. 16) has shown 
that the higher confidence assignments (|Score| ≥0.5) are more reliable. (# In this column, NA 
indicates no major stability impact detected. Overpacking means atomic distance less than 2.5 
Å if not specified. *: when available the mRNA level percentage to the wildtype is used to 































p.L41F 1phz_A   10% 91% 0.11 88% -0.57 -0.35 
NA(overpacking 








p.G46S 1phz_A   0.1% 3% 0.03 
Not 
stated 
-0.05 -0.90 backbone strain 
classic 163; 
mild 157 







p.D59Y 1phz_A   92% 100% 0.92 
Not 
stated 
-0.21 1.27 on surface MHP 44 










p.I65T 1phz_A   26% 25% 1.04 100% 
p.I65T 1phz_A   27% 25% 1.08 
Not 
stated 



































p.E76G 1phz_A   85% 100% 0.85 
Not 
stated  
0.95 -0.55 saltbridge lost NA 
p.T92I 1phz_A   76% 91% 0.84 98% 2.32 1.21 










164; 166; 168 











p.D143G 1j8u_A   33% 100% 0.33 
Not 
stated 
-1.12 1.30 on surface classic 169 
















p.R158Q 1j8u_A   10% 100% 0.10 100% 
p.R158Q 1j8u_A   10% 100% 0.10 
Not 
stated 








p.P211T 1j8u_A   72% 63% 1.15 104% 0.62 0.73 on surface classic 166 







p.R243Q 1j8u_A   10% 10% 1.00 100% 
-0.90 -1.34 saltbridge lost 
classic 157; 
162; mild 44 
p.R243Q 1j8u_A   10% 10% 1.00 
Not 
stated 










p.P244L 1j8u_A   70% 100% 0.70 100% 
p.G247V 1j8u_A BH4 4% 56% 0.07 
Not 
stated 
-2.94 -1.82 backbone strain NA 






















157; 162; 164 
p.R252
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p.L255V 1j8u_A BH4 3% 8% 0.38 100% 
-2.15 0.93 NA NA 
p.L255V 1j8u_A BH4 13% 18% 0.72 
Not 
stated 





p.A259V 1j8u_A   3% 6% 0.50 100% -2.91 -1.32 overpack 2.51 Å classic 157 









p.R261Q 1phz_A   30% 30% 1.00 
Not 
stated 
p.R261Q 1phz_A   100% 100% 1.00 100% 









p.R270S 1j8u_A TIH 3% 3% 1.00 100% 










p.E280K 1j8u_A FE,TIH 0% 0% NA 
Not 
stated 
-2.83 -1.34 saltbridge lost 
classic 157; 
162; 164; 166; 
moderate 






0% 0% NA 100% 
-3.85 0.47 on surface 
classic 157; 




1% 1% 1.00 100% 

























164 p.L311P 1j8u_A   1% 1% 1.00 100% -3.21 -1.08 
p.A322G 1j8u_A BH4 75% 105% 0.71 91% -0.37 1.08 on surface MHP 164 




















p.S349L 1j8u_A TIH 0% 0% NA 
Not 
stated 





162; 164; 166 
p.V388
M 
1j8u_A   43% 96% 0.45 
Not 
stated 





1j8u_A   43% 100% 0.43 100% 
p.A403V 1j8u_A   100% 100% 1.00 100% 0.46 -0.78 
NA 
(overpacking 
2.53 Å; on 

















p.R408Q 2pah_A   55% 91% 0.60 93% 
p.R408
W 







157; 164; 166 
p.R408
W 
2pah_A   1% 1% 1.00 100% 
p.R408
W 
2pah_A   3% 3% 1.00 102% 









































Fig. 3.2 shows the distribution of experimental total protein activity (vertical axis) and protein 
level (horizontal axis). There are multiple experimental protein levels for three mutations, 
R158Q, R261Q, and Y414C, are inconsistent. 30 of the 35 mutants categorized as 
destabilizing by the SVM are consistent with aspects of the experimental data in accordance 
with expectations for category 1 and 2 mutations. Conversely, 8 of the 11 assigned as not 
destabilizing, show close to normal protein level (more than 50% of normal level), also 





Figure 3.2. The relationship between stability impact and experimental measurements 
of mutant enzyme activity and protein level. 66 experiment measurements for 46 mutations 
are plotted by percentage of wild-type protein level (X axis) and enzyme activity (Y axis). 
Both axes are normalized by the mRNA level compared to wild-type, where available. 
Experimental results for differing independent measurements of the same mutation are 
connected by double headed arrows. Each point is colored according to the predicted 
mechanism of action, with blue for an assignment of destabilization, green for an assignment 
of normal stability, and red circles indicating an involvement in ligand binding. The size of 
each point is proportional to the confidence of the computational assignment. Near the origin 
there is a cluster of 29 points for 20 mutations (red dashed box). 16 of these mutations (24 
experimental results) are blue, and 4 mutations (5 experiments) are green. Most predicted 
destabilizing mutations show significantly reduced protein level (<50%), while most of the 
mutations with no stability assignment have close to wild-type protein level. All but one of 
the mutations close to an active site (red open circles) show low total activity, consistent with 







Subsection 2. Category 1: 28 missense mutations are expected to affect stability only 
28 of the 35 mutations with destabilization assignments are remote from any known ligand 
binding or the catalytic site, and so are expected to have a low experimental protein level, and 
wild-type specific activity. 16 of the 28 (F39L, G46S, L48S, I65T, A104D, P122Q, R157N, 
F161S, R243Q, R252G, R252Q, R252W, A259T, A259V, L311P, R408W) have protein 
levels less than 50% wild-type, as expected. Of these, all but two have wild-type specific 
activity. The two exceptions, F39L and L48S, have approximately three fold higher specific 
activities than the wild-type. These mutations lie in the regulatory domain, suggesting a 
possible explanation for the high activity level. The 16 mutants are classified into clinical 
categories of mild PKU (A104D), moderate PKU (F39L, L48S, I65T), and classic PKU 
(G46S, R243Q, R252G/Q/W, A259V, L311P, R408W). 
 
Nine of remaining mutations expected to affect stability only (L41F, R68G, R68S, E76G, 
G218V, P244L, A309V, A403V, R408Q) have reported experimental protein levels greater 
than 50% of wild-type (all 100%, except one of the R408Q experiments with 70%), 
inconsistent with the computational assignment. For five of these mutations, there is other 
experimental evidence supporting an impact on stability. R68S, P244L, A309V, and R408Q 
all exhibit BH4 responsiveness, that is, the disease phenotype is relieved by oral 
administration of BH4.
171
 Additionally, in in vitro experiments, A309V (moderate or classic 
PKU) and R68S (mild PKU) have been shown to have longer protein half lives in the 
presence of BH4 than in its absence,.
44; 172
 and cellular studies of R408Q (MHP or mild PKU) 
show protein aggregation.
44
 It has been suggested that BH4 acts as a chemical chaperone, 
facilitating correct folding.
44
 The standard experimental BH4 (or analog) concentration
173
 is 
10 times higher than that of physiological conditions
174; 175




demonstrated to result in significant variation in experimental results.
176
 Thus, for these four 
mutations, the observed high experimental protein levels are consistent with masking of 
destabilization effects by the presence of excess BH4. For a fifth mutation, G218V (classic 
PKU), a large fraction of aggregates have also been reported.
44
 A sixth mutation, R68G, 
appears from the structural context to be destabilizing, but no disease classification or 
additional experimental evidence is available in this case. The three remaining inconsistent 
mutations in this category are likely false positives of the computational method. Two (E76G 
(no disease classification) and A403V (mild PKU)) have low impact (i.e. inconsistent) 
assignments from the sequence conservation method. Visual inspection of the third, L41F (no 
disease classification), suggests it may not affect stability.  
 
The final three mutations expected to impact stability only, R158Q, R261Q, Y414C, (classic, 
moderate, and mild PKU or MPH respectively) have inconsistent experimental results. At 
least one experiment is consistent with that assignment for each mutant, with less 50% of 
wild-type protein level. Two of these R261Q and Y414C have short in vitro half lives, and 




Overall, the computational category assignment is consistent with at least some of the 
experimental evidence for 24 (16 with low protein level, five with high protein level but other 
experimental evidence for destabilization, and three agreeing with at least one experimental 
low protein level result) of the 28 in this category. One more, R68G, is likely destabilizing, 
but requires additional experimental evidence. The remaining three (G68G, E76G, and 





Subsection 3. Category 2: Seven missense mutations are expected to affect both 
stability and molecular function 
There are seven mutations (G247V, L255S, R270S, E280K, S349L, S349P and Y277D) with 
atomic contacts of 6.5 Å or less to the phenylalanine substrate, the BH4 cofactor or the Fe
++ 
ion, and that are assigned as destabilizing by the structure SVM. These mutant proteins are 
therefore expected to exhibit a combination of lower specific activity and a lower total 
protein level. Six of the seven (G247V, L255S, R270S, E280K, S349L, S349P) have protein 
levels less than half or in one case close to half (G247V, 56%) that of wild-type, and very low 
protein activity, consistent with expectations. Clinical categories are available for E280K, 
S349L, and S349P, and are all “classic PKU”, consistent with the results and with 
experiment.  
The remaining mutant in this category, Y277D, has an experimental activity of zero, and is 
classified as mild or classic PKU, consistent with the profile SVM assignments. But the 
measured protein level is reported as 99% of wild-type, inconsistent with a modest 
confidence stability assignment. This may be a computational false positive with respect to 
stability. 
 
Subsection 4. Category 3: Nine mutations are expected to impact molecular function 
only 
A total of nine mutations are classified as high impact by the sequence conservation method, 
classified as not destabilizing by the stability method, and so are expected to impact 
molecular function but not stability, implying wild-type protein levels and lower activity.  
Four of these, L255V, P281L, A322G, and L348V have atomic contacts of 6.5 Å or less to a 
ligand. Experimental data for two, A322G and L348V, are consistent with expectations, with 




activity, but also low protein level. Both are in direct contact with the BH4 cofactor, and 
would disrupt binding substantially. Experimental measurements for P281L show <1% or 
non-detectable for both total enzyme activity and protein level 
177; 178
, and the mutant is 
classified as classic PKU. For L255V, two independent experimental measurements give 
<3% and 13% of wild-type activity, and 8% and 18% of total protein 
179; 180
. For both 
mutants, it is probable that the low protein level is consequence of reduced protein stability, 
arising from reduced ability to bind BH4, rather than direct destabilization of the protein 
structure. 
The other five mutations in this category, K42I, D59Y, D143G, V388M and R413P, are not 
near to any known ligand binding or catalytic site. Four are located on the protein surface. 
Two of these, D143G, and V388M, exhibit low total protein activity, and have near 100% 
wild-type protein levels, consistent with the computational assignments. D143 is a conserved 
residue located on the dynamic loop (residue 136~151) at the entrance to the active site, and 
is believed to play a role in the access of substrate and BH4 to the active site 
160; 161
 and so the 
mutant likely affects catalytic efficacy. Although two independent reports give V388M wild-
type protein level, it has been demonstrated to affect tetramer formation, and co-expression 
with additional GroESL chaperone partly overcomes that effect.
181
 Also, it has a shorter in 
vitro half life, and patients respond to BH4 supplement,
44; 172
 all suggesting a destabilization 
effect. There are no inter-domain or inter-subunit contacts. It is possible that the larger 
exposed hydrophobic mutant side chain is responsible for a greater tendency to aggregate.   
K42I has atomic contacts with a neighboring subunit, suggesting interference with tetramer 
formation, although this was not detected by the computational analysis, and the structural 
context does not appear destabilizing. D59Y has 92% of wild-type activity, and is a MHP 
class mutant. The sequence conservation confidence score is low (-0.21), all suggesting this is 
a false positive. R413P has a low protein level and low activity, and inspection of the 




Overall, for this category, there are two likely false negatives for stability impact (K42I and 
R413P), and one marginal false positive general high impact assignment (D59Y), and one 
unclear (V388M). The computational assignments for the other five are consistent with the 
experimental evidence. 
 
Subsection 5. Category 4: Two mutations are assigned low impact by both the 
sequence conservation and stability method 
Two mutations, T92I, and P211T, are assigned low impact by both computational methods. 
Both sets of experimental results show close to normal activity and protein levels, consistent 
with the analysis results. Also reasonably consistent, T92I is assigned to the mild MHP 
category of disease, suggesting a subtle effect on protein function. Inconsistent with both 
experiment and computational analysis, P211T is assigned to the “classic PKU” category, 
based on a single functionally hemizygous patient genotype.  
 
Section 4 Discussion  
We have used the two computational methods to categorize the expected impact of a set of 46 
PKU related mutations on the structural stability and molecular function of PAH, and 
compared the results to experimental data on in vivo like activity and protein levels, as well as 
the severity of disease. As in the general study of monogenic disease mutations,
33
 about ¾ of 
the PAH mutations are assigned a high impact on protein stability A primary objective was to 
test whether this computational assignment of a high fraction of mutations affecting protein 
stability is accurate. In this study, 35 out of 46 mutations are assigned as destabilizing. Of 
these 35 mutations, the experimental data for 30 support a role for destabilization, a true 




an impact on molecular function are also reasonable, with three possible false predictions out 
of 16 (categories 2 and 3). Finally, the two cases where no functional impact is assigned by 
the computational methods agree with experiment. Even in the best of circumstances, 
comparisons between computational and experimental results are never entirely 
straightforward. In this study, because of variability in the experimental results and 
conditions, as well as the small number of cases considered, these accuracy rates are quite 
approximate. Variability in experimental results may arise from a number of factors, 
including the use of non-natural cofactors, or high cofactor concentrations, and can result in 
misleading disagreements with some computational assignments.. Never-the-less, the results 
broadly confirm the primary conclusion from the earlier computational work that 
destabilization plays a major role in monogenic disease, at least for this protein, and also 
support the estimated false positive rates. 
The general tendency for PKU mutants to be associated with normal mRNA levels together 
with reduced protein levels and reduced total activity has been noted before.
158
 The 
computational methods have allowed us to firmly link these observations to reduced stability 
of the protein three dimensional structure. Earlier comparison of the stability method results 
with experimental data for a set of site directed mutations in bacterial and phage proteins 
established that destabilizing monogenic disease mutations typically reduce the free energy 
difference between the folded and unfolded state of a protein by 2 to 3 Kcal/mol,
33
 and the 
PAH mutations are likely similar in this regard. Given the typical range of free energy 
difference between the folded and unfolded state of a protein of 5 to 15 Kcal/mol, this level 
of destabilization would not have a measurable effect on in vitro activity, but evidently is 
usually critical in vivo.    
There are two possible mechanisms. One mechanism is that these mutations sufficiently slow 
folding that a much smaller number of mature protein molecules are produced. Quality 




have been known for some time.
182
 Available data on bacterial proteins show that about 40% 
of destabilizing mutations affect folding rate, but there are no extensive data for human 
proteins. The second possible mechanism is that the large increase in the concentration of 
unfolded protein (typically approximately 100 fold) produced by a 2-3 kcal/mol 
destabilization results in a high scavenging rate by molecular chaperones such as HSP90, 
which recognize unfolded protein molecules and target them to the mediated protein 
degradation system with the aid of proteins such as CHIP 
183
 . In either case, the result is a 
much lower in vivo concentration of proteins carrying destabilizing mutations. 
 
Section 5 Conclusions 
There are three primary conclusions from this analysis of monogenic disease causing 
mutations in phenylalanine hydroxylase. First, the results support the conclusion of an earlier 
computational study that the large majority of missense mutations that cause monogenic 
disease involve destabilization of the protein structure. Second, the results confirm the link 
between destabilization and low in vivo protein levels. Third, although the numbers are small, 
the results also support the previous benchmark accuracy levels of the computational 
methods. 
 
Section 6 Materials and Methods 
Subsection 1. Data source 
The experimental data for a set of 46 PKU-causing missense mutations of PAH and the 
results of 66 transient expression experiments in mammalian cell hosts was taken from 
PAHdb 11. All the wild-type and mutant cDNAs in this set have been expressed in monkey 




reactive protein level and sometimes mRNA level measured and reported as a percentage of 
wild-type.  
 
Subsection 2. Templates selected for modeling missense mutations 
Under physiological conditions, human PAH is a homo-tetramer, with each subunit 
composed of three domains. From N terminal to C terminal these are the regulatory, catalytic 
and tetramerization domains. To date, no experimentally determined structure of the complete 
human molecule is available., Three PDB structures were selected to model specific 
mutations in different domains based on crystal structure resolution, structure quality, and 
coverage: 1j8u, human PAH structure containing mainly the catalytic domain (resolution 
1.50Å, R-free 0.203, in monomeric form); 2pah, human PAH structure covering the catalytic 
and tetramerization domains (resolution 3.10Å; R-free 0.326, in a tetrameric complex); and 
1phz, rat PAH structure covering the regulatory and catalytic domains (resolution 2.20Å; R-
free 0.297, in a dimeric complex). 
 
The high resolution human 1j8u structure was used to model catalytic domain mutations. 
Regulatory domain mutations were modeled using a homology model of the human domain, 
based on the rat 1phz structure, as were three catalytic domain mutations, R261Q, R413P, 
and Y414C, that are in contact with the regulatory domain across a subunit interface. Rat 
PAH protein has 93% sequence identity with human PAH. There are no insertions or 
deletions in sequence between the two proteins. Main chain coordinates were taken directly 
from the rat structure. Side chains conformations were optimized using SCRWL.
184
 Catalytic 
domain mutations R408W and R408Q are in contact with the tetramerization domain of 





Subsection 3. Structure and sequence conservation methods for missense mutation 
impact analysis 
The detailed methodology has been described previously.
32; 33
 The stability method 
optimizes the side chain conformations of a mutated residue and calculates 15 
stability factors, including solvent accessible surface area, electrostatic interactions, 
steric clashes, buried hydrophobic area and local main chain flexibility. Based on 
these factors, a Support Vector Machine model (classifier) was trained using a set of 
monogenic disease causing mutations from the HGMD database and a non-disease 
control set of genomic variation between human and closely related mammals. For 
the present project, the model was retrained, excluding all PAH variants. False 
positive and false negative rates were assessed using the same bootstrap procedure as 
in Yue & Moult 
32
. The false positive rate and false negative rates for the retrained 
model are 16.4% and 26.6% respectively, little different from the published model 
with 17% and 26%. Note that the high false negative rate is expected, since not all 
monogenic disease mutations include an effect on stability.  
 
The sequence conservation method has also previously been published.
32
 Five 
features are used to characterize the relative sequence conservation across the protein 
family at each residue position and the probability of accepting a specific substitution 
at that position. The same training data as for the stability method was used to train 
another SVM classifier. For the present application, the model was again retrained 
omitting all PAH variants, resulting in false positive and false negative rates of 9.5% 
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Chapter 4: Single Base Variants in Protein Interfaces and 
Their Role in Disease  
 
Section 1 Abstract 
It has been suggested that missense single base variants that change an amino acid in the 
interface between two proteins may play a significant role in disease, and that interface 
substitutions have unusual properties in terms of the availability of compensating changes 
(Haag and Molla, 2005 
185
). To address these issues, we have used the impact analysis 
methods in SNPs3D to investigate the properties of interface variants found in a set of 1726 
proteins with structural information available for at least one interface. Three classes of 
variants were examined: those in monogenic disease, those arising from common human 
SNPs, and those fixed in closely related mammal orthologs of the human proteins. Overall, 
all three classes of variant display a relative density in interfaces midway between that of 
surface regions and the protein interior, consistent with an intermediate level of sensitivity to 
substitutions. Disease mutations have opposite enrichment patterns to inter-species variants 
and SNPs. The latter two have the highest relative density on the surface and lowest in the 
interior, whereas disease mutations have the highest enrichment in the interior. Disease 
mutations are found to be more concentrated in heteromeric interfaces than homomeric ones, 
suggesting a greater sensitivity to disease mutations. Population SNPs share a similar 
enrichment distribution to that of species variants, but with a less pronounced difference 




Section 2 Introduction 
Protein-protein interfaces play a key role in many aspects of protein function, including many 
cases of signal transmission mediated through transient complexes, regulation of protein 
activity through the binding of co-factor proteins, for example GTPase Activating Protein 
(rasGAP) binding to KRAS;
125
 function activation by regulated homo-dimer formation, for 
example members of the DRP kinase family;
186
 and allosteric control in constitutive 
complexes such as hemoglobin. Formation of a homomeric complex is frequently essential to 
achieving adequate thermodynamic stability of the folded state. Protein complexes display a 
wide range of binding affinities from milli-molar to sub pico-molar. Mutagenesis studies have 
established that there is also a wide range of contribution to binding by individual residues, 
with side chain truncation at some „hot spot‟ positions reducing the free energy of association 
by more than 2 Kcal/mol.
115
 Complexes may be homomeric (formed from identical 
constituent proteins) or heteromeric. Complexes have also been classified 
74; 111
 as obligate 
(under in vivo conditions, the components are only functional as part of the complex) or 
transient (the components are found separated or in complex, depending on circumstances, 
cofactors, and covalent modification state).  
 
As more experimental structures of complexes have become available, there have been a 
number of studies of interface properties. Primary findings are that interface residues are less 
conserved within protein families than are those in the interior;
91; 187; 188
 that packing is less 
efficient in interfaces than in the interior, with a higher level of buried water molecules;
101; 104; 
189
 and that there is greater propensity for polar and charge interactions in interfaces than in 
the interior.
97; 104
 The differences between interfaces and the interior are more pronounced in 
transient interfaces than in obligate ones.
111; 190
 Overall, interfaces are found to have 




Knowledge of interface properties has been used to identify the presence of interface forming 
regions on the surface of proteins 
98; 188
 and to predict the mode of interaction at atomic 
detail.
111
 Community wide blind tests have established the partial effectiveness of the latter 
methods.
191
 There has also been some success in designing protein binding interfaces,
192; 193
 




Since protein interfaces play such a central role in many biological processes, their response 
to genetic variation is also of interest. For instance, how tolerant are interfaces to residue 
substitutions, are disease related variants common there, how variable are interfaces between 
species? It has been suggested that interfaces may be relatively amenable to accepting 
compensating mutations (cases where a first unfavorable mutation is later followed by a 
second mutation that restores fitness) because of a greater malleability than that of protein 
interiors.
185
 Availability of large amounts of genome sequence and genetic variant data, 
together with structural data, now provides an opportunity to address some of these issues. 





Here we use structural and genetic data to investigate the occurrence of genetic variants in 
human protein interfaces and to compare those characteristics with that of variants occurring 
in other environments. Three types of variant are included: inter-species variants – amino 
acid differences that have been fixed between human and closely related mammals; non-
synonymous single nucleotide polymorphisms (SNPs) within the human population, resulting 
in amino acid substitutions present in a subset in individuals only; and single residue 
mutations involved in disease. Whereas the genetic data is distributed over all human protein 




make use of conservative comparative modeling of protein structure to further leverage the 
data. 
 
Section 3 Results 
Subsection 1. Data 
Protein complexes were extracted from the Protein Data Bank (PDB, www.pdb.org), and 
augmented using conservative comparative modeling. Sets of non-synonymous SNPs, disease 
related mutations, and inter-species single base variants were mapped on to the complexes, 
and residues were assigned as surface, interior or interface. Details are given in Methods, and 
Supplementary Table S4.1 summarizes the data. Protein interfaces were subdivided into those 
containing only identical polypeptides (homomeric) and heteromeric, where two or more 
distinct polypeptides are involved. The final data set contains structural information for 1778 
nsSNPs in 779 genes, 2717 disease related mutations in 189 genes, and 2944 species variants 
in 107 genes, all part of protein complexes. Figure 4.1 summarizes the fraction of residues 
and variants in each structural context. About 20% of the residues are in interfaces, with 2/3 
of those in homomeric complexes, and 1/3 in heteromeric complexes. Compared to the 
residue distribution, there is a smaller fraction of SNPs in the interior and more in the 
interface and on the surface. Species variants have a strikingly high fraction (60%) on the 
surface. In contrast to the other distributions, the highest fraction of disease mutations (50%) 






Figure 4.1. Overall distribution of amino acid residues for three types of non-
synonymous single base variants across the interior, surface, and interfaces of protein 
complexes. Interfaces are divided in homomeric and heteromeric. Each class of variant 








Subsection 2. Distribution of substitutions over the structural environments 
The relative propensity for each of the three types of variant to lie in each of the three 
structural environments – surface, interior and interface, is seen more clearly using 
enrichment ratios (or propensity, introduced by Jones and Thornton
97
). Briefly, for a 
particular substitution type and structural environment, the enrichment ratio is the density of 
those substitutions in that environment, divided by the density of that substitution type over 
the whole protein. Thus, an enrichment ratio greater than one reflects a preference of 
substitutions for the selected environment. Figure 4.2 shows the enrichment ratios for the 
three classes of variant. Relative variant densities differ markedly over the three 
environments. The partitioning of species variants shows the strongest signal. Here there is a 
relative enrichment of about 50% on the surface, a depletion of about 40% in the interior, and 
an intermediate level in the interfaces, closer to that of the interior. SNP preferences are less 
polarized, but follow the same pattern – greatest enrichment on the surface, intermediate in 
the interfaces, and lowest in the interior. We and others have observed the difference between 
interior and surface for SNPs before,
69; 72
 and ascribe it to the more stringent requirements for 
satisfying steric and electrostatics restraints in the interior compared with the surface. This 
effect is explored further later. The similar but weaker tendency in SNPs likely reflects the 
fact that selection against these is incomplete.
24
 In support of that view, in a previous study, 
we found that approximately 1/3 of all non-synonymous SNPs have a high impact on protein 
structure or function, whereas most species variants do not.
32
 The finding that interface 
variant density is intermediate between the surface and the interior supports the view that 
interface environments are more tolerant of substitutions than the interior of a protein.
185
  
Disease mutations display environment preferences markedly distinct from the other two 




the average over all environments, and there are almost equal densities in the interior and in 
interfaces, enriched by about 25% compared with the average. These preferences are 
consistent with an earlier analysis that showed many of these disease related mutations have a 
high impact on protein thermodynamic stability,
33
 and, as shown later, substitutions in the 
interior and interfaces are more likely to have an effect on molecular function than those on 





Figure 4.2. Enrichment ratios of SNPs, species variants, and disease mutations for the 
interior, interface and surface of protein complexes. The strongest polarization is 
displayed by species variants, with higher relative density on the surface, intermediate in the 
interfaces, and lowest in the interior. SNPs show the same pattern, but with less pronounced 
preferences. By contrast, disease mutations are enriched in the interior and in interfaces, and 









Subsection 3. Distribution of variants for homomeric versus heteromeric interfaces 
Figure 4.3 shows the interface enrichment ratios for homomeric and heteromeric interfaces 
separately. SNPs and species variants have the same enrichment in the two types of interface 
within sampling error, but the disease related mutations have a higher enrichment in 
heteromeric interfaces than in homomeric ones. (Wilcoxin rank sum test, P=0.050) 
 
 
Figure 4.3. Enrichment ratios for homomeric and heteromeric interfaces.  
Heteromeric interfaces are enriched in disease mutations compared with homomeric 






Homomeric interfaces are nearly all obligate whereas the heteromeric are a mixture of 
obligate and transient interfaces. (Transient complexes are those for which the components 
exist both separately and as a complex under normal in vivo conditions, for example, a 
growth factor and its receptor). Residues that form part of transient interfaces experience two 
types of environment – solvent and protein interior, whereas obligate interfaces are required 
to accommodate only a protein interior like environment. Previous studies have shown that 
the distribution of physicochemical properties in transient and obligate interfaces is 
different.
111; 190
 To see if the difference between homomeric and heteromeric interfaces may 
be related to their greater transient nature, we divided the subset of 68 distinct disease related 
proteins that have heteromeric interfaces into transient and obligate, based on the available 
literature.
111
 The interfaces of 61 of these proteins could be unambiguously assigned with 37 
as part of transient complexes and 24 part of obligate complexes. Amongst these, there are 95 
interface mutations in 18 proteins involved in heteromeric transient complexes, and 104 
interface mutations in 18 genes in obligate interfaces. Transient complexes include fibroblast 
growth factor receptor with its growth factor, G protein complex, cyclin-dependent kinase 4 
with its inhibitor, thyroid stimulating hormone receptor with its hormone, tumor suppressor 
BRCA1 with BRCA1 interacting protein, von Hippel-Lindau disease tumor suppressor with 
elongin. Obligate complexes include hemoglobin subunits, electron-transfer-flavoprotein 
complex subunits, troponin subunits, and the mitochondrial respiratory membrane protein 
complex. The other interfaces in these sets do not contain any disease related mutations. The 
full list of complexes is given in the Supplementary table S4.2.  
 
Figure 4.4 shows interface enrichment ratios for these two types of environment compared 












Figure 4.4. Environment enrichment ratios for disease mutations in obligate and 
transient protein complexes.  
There is a probable greater relative enrichment of disease mutations in the interfaces of 







Subsection 4. Incidence of high impact SNPs in different environments 
Disease related mutations are expected to have a high impact on molecular function, whereas 
species variants will have a low impact. As noted earlier, these characteristics determine the 
contrasting environment enrichment patterns for these classes of variants. Population SNPs 
are a mixture of high and low impact, and in a previous study, we found that up to 1/3 of all 
non-synonymous SNPs have a high impact on molecular function.
32
 It is therefore of interest 
to examine the environment enrichment of the high and low impact SNP subsets separately. 
For this purpose we performed a molecular impact analysis using a previously developed 
classification method.
32
 This method relates the level of molecular impact to protein sequence 
conservation at a substituted position and to the substitution frequency pattern in the protein 
family. The more relatively conserved a column of interest in the protein sequence alignment 
and the less commonly observed a residue substitution, the more likely such a residue change 
will have a functional impact. The method uses a support vector machine trained on the 
disease mutations from HGMD
6
 and the control set of inter-species variations to assign a 
residue substitution as high impact or low impact on molecular function. It has previously 
been applied to the set of frequency validated SNPs in dbSNP
13
. We also generated a dataset 
containing all possible SNPs by introducing every single base change in each codon in the 
coding region of each gene (except the start and termination codons). Molecular impact 
analysis of this variant set provides a measure of the fraction of high impact SNPs that would 
be expected in each environment if there were no selection pressure. 
 
Overall, 34% of the observed SNPs are assigned as high impact, and 60% of the all-possible-
SNP set are so assigned. Figure 4.5 shows the fraction of high impact SNPs for the observed 




the interior, an intermediate fraction are in interfaces, and the smallest high impact fraction is 
on the surface, a reversal of the trends seen for all SNPs. There is no significant difference 
between homomeric and heteromeric interfaces. High impact SNPs from the all possible set 
follow the pattern of the observed high impact ones, but with a larger fraction in each 
environment. These trends again suggest that the interfaces have a structural stringency 
intermediate between that of the interior and the surface. The lower fraction for observed 
SNPs versus all possible ones reflects the effect of selection. As noted earlier, SNP selection 





Figure 4.5. Fraction of high impact SNPs in different environments (colored bars) and 
fraction of all possible SNPs that produce high impact in each environment (open bars). 
Interfaces have an intermediate fraction of high impact variants, for both the observed and all 
possible sets. Lower fractions for observed high impact SNPs versus all possible ones reflect 







Subsection 5. High density and low impact of interface SNPs in immune proteins 
A striking feature of the SNP data is that a high proportion is in immune system proteins: the 
72 immune proteins have an average of 4.7 validated SNPs per protein, while the 707 non-
immune proteins have an average of 2.0. Closer inspection showed that contrast is even 
higher for interface SNPs: there is an average of 2.4 per protein in the immune proteins 
versus 0.37 in the non-immune set. Figure 4.6 shows the fraction of high impact SNPs for 
each environment in the immune proteins with heteromeric interfaces, together with the 
fraction of all possible SNPs that are high impact. The fraction of high impact SNPs in the 
interfaces is very low (about 5%) and much lower as a fraction of that for all possible SNPs 
than the other environments. These observations – that there are many SNPs in immune 
protein interface, but that only a small fraction are high impact – reflect the ongoing high rate 
of positive selection in some of these proteins. Indeed, the proteins with the most SNP 
enriched interfaces are HLAs, for example, HLA-DRB1 (26 interface SNPs from 35 total); 
HLA-DRB4 (21 of 29); MICA (MHC class I polypeptide-related sequence A (18 of 28); 





Figure 4.6. Fraction of high impact SNPs in immune proteins (filled bars) and fraction 
of all possible SNPs that are high impact (open bars). The surface and interior of immune 
proteins show a similar relationship between observed and possible high impact SNPs to that 








Section 4 Discussion 
In this study, we have examined the relative propensity of three types of genetic missense 
variant for protein interfaces compared to other types of protein environment. The primary 
conclusions are as follows: 
1. As has been found for other properties, the propensity for missense variants to be 
tolerated in interfaces is intermediate between that of the protein interior and protein 
surface. All three variant classes show this feature, but there are detailed differences. 
Disease mutations have a relative enrichment statistically indistinguishable for that of 
the interior, and the enrichment ratio for SNPs is also closer to the interior than to the 
surface. The fraction of possible variants in interfaces that are deleterious is also 
found to be intermediate. 
2. Disease mutations have an opposite enrichment patterns to that of species variants 
and SNPs. Species variants and SNPs have the highest relative density on the surface, 
and disease mutations have the highest value in the interior. This pattern has been 
observed before in comparison of disease mutations and SNPs
71; 72
 and is attributed to 
the difference in tolerance for variation in the two environments. As the analysis 
shows, a much higher fraction of all possible substitutions in the interior have a 
deleterious impact on protein function than on the surface (about 75% versus 45% 
with the criteria used).  
3. Population SNPs show a similar enrichment distribution across environments to that 
of species variants, but with a less pronounced difference between environments. 
This observation is consistent with the fact that SNPs are at an intermediate stage of 
selection – some will eventually become fixed within the species, others will fade 
away,
24
 in a process partly determined by selection and, especially in a species with a 






4. Disease mutations appear more enriched in heteromeric interfaces than homomeric 
ones, and there are indications that this tendency may reflect a greater enrichment in 
transient rather than obligate interfaces. However, more data is needed to establish 
whether this is in fact the case. Such a propensity would be consistent with 




5. The estimated fraction of high impact SNPs follows pattern seen for the fraction of 
all possible variants that are high impact in each environment, but with values about 
40% lower in each case, including the interfaces. The latter observation again 
supports incomplete selection against deleterious SNPs. (Species variants have a 
predicted high impact fraction of only about 10%, a level presumed dominated by the 
false positive rate of the method).  
6. In contrast to the general pattern, immune proteins, which have a higher density of 
SNPs overall, especially in interfaces, show a much lower fraction of high impact 
SNPs in interfaces than for other proteins. The combination of a high density of SNPs 
and a low fraction of high impact ones in immune interfaces likely reflects the 
ongoing positive selection of the immune response. This point is reinforced by the 




Overall, the results support the view that interfaces are rather more pliable in accepting amino 
acid substitutions than the interior of proteins, but the results also reveal a more complex 
picture. It should be born in mind that the definition of an interface residue will affect the 
results – a more restrictive one, such a minimum threshold area change for a residue on 





Section 5 Materials and Methods 
Subsection 1. Variant Datasets 
Non-synonymous SNPs: 72855 non-synonymous SNPs were extracted from dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/, version 128), and filtered to remove all variants 
without an allele frequency entry. This procedure removes many erroneous entries from the 
data, and also removes contamination by rare variants, such as those involved in monogenic 
disease. The resultant set generates 27983 residue substitutions at 24557 positions in 10493 
human genes.  
Disease Mutations: Disease mutations were obtained from the Human Gene Mutation 
Database (HGMD)
6
 (as of 02/09/2002). An early version of HGMD is selected, since later 
ones contain substantial amounts of data for variants that are only associated with disease 
risk, rather than directly implicated, and so are not suitable for present purposes. The set 
consists of 10,263 single residue variations in 731 human genes. 
Inter-species variants: The species variant dataset consists of 16,682 residue differences 
between 346 human proteins from the HGMD disease mutation set and their orthologs in 
other mammals, with the restriction that an ortholog must have at least 90% sequence identity 
to the corresponding human protein, over at least 80% of the human protein length.  




Subsection 2. Mapping to protein structure 
The amino acid sequences of all isoforms for 18,444 human genes (human genome build 
36.2) were searched against sequences in the Protein Databank (PDB, as of 1/08/2008) using 
BLASTP.
199
 All hits to X-ray structures with a resolution of 3.0Å resolution and alignments 




from 3332 genes met these criteria. Multiple hits for an isoform were ranked by a priority 
order of first sequence identity, then alignment length, and lastly structure resolution, and the 
top rank selected. Finally, for each gene, the isoform with the longest alignment to a structure 
was selected. The resulting set of alignments covered an average of 54% of the residues in the 
3332 genes. 
 
Subsection 3. Construction of structure models 
For cases where the sequence of the selected, PDB entry is not identical to that of the 
isoform, a comparative model was built, as previously described.
33
 Co-ordinates of the 
biological unit for each selected structure were taken from the PQS database
104
,by matching 
PDB IDs. The backbone is first constructed by copying aligned regions of the chosen 
template structure. Residue equivalents between template and target structure are mapped 
using a CLUSTALW alignment. Side chain coordinates are built using SCRWL3.
184
 1726 of 
the 3332 proteins with structural coverage contribute at least one interface to a complex, and 
these formed the set for analysis. 
 
Subsection 4. Definition of Environment and interface Classes 
Residue solvent accessible area for complexes and subunits was calculated using STRIDE
80
 
with default settings. Interior residues are those with less than 20Å
2
 surface area; interface 
residues are those for which there is a change in surface area between the complexed and 
monomeric states. All other residues are defined as surface. Homomeric interfaces were taken 
to be those between chains with sequence identity of at least 95% over at least 80% of the 
length, obtained using bl2seq.
199
 Interfaces which did not meet these criteria were further 




those with different gene IDs were taken as heteromeric. The reminder, for which component 
chains have identical gene IDs but are less than 95% sequence identity, were rejected as 
ambiguous. 
 
Subsection 5. Relative enrichment ratio calculation 
The enrichment ratio for environment „ ‟ (interior, interface, or surface) in a protein monomer 
„  ‟ is defined as:  
 
     
  
   
  
   
 
    
 
  




   = number of variants in environment  ; 
  
   = number of residues in environment  ; 
and the sum   is over the three environment classes.   
Enrichment ratios for heteromeric, homomeric, immune, and non-immune interfaces are 
calculated including only interfaces meeting the appropriate definitions. 
The average enrichment ratios for a set of  monomers is calculated as  
 
            (2) 
 
Zero     values are included. For four proteins, there are no interior residues, and so no 
contribution to those sums. Note that this mean of ratios expression is preferred, rather than 
the alternative ratio of means, calculated as:  
 
       
      







since the latter may be subject to Simpsons paradox.
200
 In fact, results from the two methods 
are in close agreement, except for the heteromeric interfaces, where the very uneven SNP 
distribution in the Immune proteins distorts the ratio obtained with equation 3. Enrichment 
ratios were also calculated taking into account the effect of transition/transversion mutation 
rate bias and the CpG context.
201
 Results calculated in this way are not significantly different, 
and are not included. 
 
Subsection 5. Bootstrap procedure for estimation of the enrichment ratio variance 
For a dataset of n environment ratios, the procedure randomly selects n values, allowing 
repeat selection. The mean is calculated for that set of ratios, and the selection procedure is 
repeated 10,000 times. The most probable value of the enrichment ratio is the average of the 
10,000 means, and the standard deviation of the most probable mean is that standard 
deviation of the distribution of generated means. For disease mutations in obligate and 
transient interfaces, the BCa (bias-corrected and accelerated) procedure,
202
 better suited to 
limited data, was used, utilizing the bcanon function in the R bootstrap package. 
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Chapter 5:  Discussion 
 
This thesis reports results for studies of three different classes of amino acid substitution 
observed in human proteins: somatic missense mutations found in tumors; monogenic 
disease-causing missense mutations in phenylalanine hydroxylase, and non-synonymous 
SNPs in the human population. We have also compared the properties of these variant classes 
with those of inter-species amino acid differences between human and closely related 
mammals, and all possible missense substitutions. The common theme of the work is the 
exploration of the molecular impact and distribution of missense variants in protein structure, 
with particular emphasis on disease relevance. Here, we summarize some aspects of the 
results. 
 
Section 1 The prevalence of high-impact variants 
 
The systematic application of an impact analysis method to all possible missense single base 
variants in a set of proteins shows that about 60% are expected to have a high impact in in 
vivo protein function, and this may be considered the level expected in the absence of any 
selection.. The present work has confirmed the earlier finding that, overall, about 1/3 of the 
non-synonymous SNPs investigated are classified as high impact.  
The impact analysis finds only about 10% of species variants to be high impact, and that level 
is likely dominated by the false positive rate of the method. These results are in accord with 
models of incomplete purifying selection on human SNPs.
24
 We also grouped these SNPs into 
three categories of protein environment (protein interior, protein-protein interaction 
interfaces, and the protein surface). The result revealed marked differences, with 52% of 




interfaces, and 26% on the protein surface are so classified. However, these differences track 
those of impact levels for all possible SNPs over the three environments (75% for the interior, 
60% in interfaces, 48% on the surface), consistent with selection operating independent of 
location. 
 
Somatic missense mutations identified by sequencing all exons in a set of tumors and 
matching normal tissues gave us an opportunity to examine the prevalence of high impact 
mutations in cancer. We found that in the annotated cancer genes, close to 100% of mutations 
have a high impact on molecular function, suggesting strong positive selection for this type of 
presumed driver mutation. Examination of the data for each individual cancer sample shows a 
five fold variation in the total number of missense somatic mutations per tumor, but the 
fraction of these that are high-impact is roughly constant at around 50%, close to the fraction 
of all possible missense mutations that are high impact. Assuming a similar number of drivers 
in each individual, these data suggest that in most cases, only a fraction of the high impact 
mutations are drivers. There is now a coordinated international effort to sequence many 
cancer samples, so that in future, much larger amounts of data will permit a more detailed 
analysis of the relationship drivers and high impact mutations.  
 
 
Section 2 Destabilization as the major mechanism for high-impact variants 
 
Previously, Yue, Li and Moult 
33
 found destabilization of protein structure as the major 
mechanism of monogenic disease-causing mutations. The earlier study of human population 
SNPs
32
 also found that about 60% of high impact cases are classified as destabilizing protein 




test the computational method against new experimental data. We have collaborated with an 
experimental group studying a set of 46 randomly selected non-synonymous SNPs from 16 
proteins.
123
 In each case, the wild type and SNP modified proteins were cloned, expressed, 
and where possible characterized in terms of stability and function. These properties were 
then compared with the previously recorded impact assignments from our computational 
methods, providing a bona fide blind test of the computer models. More than half of these 
variants were found to significantly destabilize the structure. All experimentally significantly 
destabilizing variants were predicted as high impact by the stability and profile methods, and 
all but two significantly stabilizing ones were predicted as low impact. In further validation, 
Chapter 3 we report a study of the structural impact of a set of mutations for a classic 
monogenic disease, phenylketonuria (PKU). The results of this study are compared with 
experimental data on in vivo protein levels and activity. Of the 46 mutations considered, 35 
(76%) are assigned as high impact on protein stability. 30 out of these 35 predictions are 
supported by in vivo experimental data. Although the experimental comparisons available are 
very limited in scope, they do reinforce the earlier conclusion that the majority of high impact 
single base variants act through destabilization of protein structure.  
Interestingly, we found that the stability effect also plays a major role in the mechanism of 
cancer somatic mutations in tumor suppressor genes. 22 of 25 mutations in tumor suppressors 
are classified as destabilizing structure. The destabilization effect also plays an important role 
in oncogenes, the other subgroup of cancer genes, but with more intricate mechanisms, such 
as destabilization of the less active conformational state, or disruption of protein complexes 





Section 3 The incidence of genetic variations at different protein structure locations  
 
In Chapter 4 we discussed the distribution patterns of SNPs, disease mutations, and inter-
species variants across three classes of protein environment. SNPs and inter-species variants 
share the same pattern of enrichment ratios, with overall enrichment on the surface, lowest 
density in the interior, and an intermediate density in interfaces. The general pattern of SNPs 
is less polarized than the inter-species variants. Monogenic mutations have the opposite 
tendency to SNPs and species variants, with most enrichment in the interior. Other interesting 
observations are that disease mutations are enriched in heteromeric versus homomeric 
interfaces, perhaps reflecting an increased propensity in transient situations; and that there is 
a high density of SNPs in immune protein interfaces but a low fraction those are high impact.  
 
Section 4 Future perspectives 
 
Finally, some future perspectives on impact analysis are discussed below. 
Our impact analysis methods only assess the effect of missense variants, even though 
synonymous mutations and those outside of the coding region may be equally relevant to 
disease mechanism, particularly for complex trait disease. Integration of other impact analysis 
procedures, such as those for alternative splicing, mRNA stability, and expression regulation 
mediated through transcription factor binding and non-coding RNAs, are needed to provide a 
more complete picture of disease mechanism. A number of methods have been developed for 
identifying transcription
203; 204
 and microRNA binding sites,
204; 205
 the signals that determine 
splicing,
206; 207
 and the secondary structure of mRNA.
208
 Many of these methods have the 




investigating the impact of single base changes.
209; 210
 The challenge lies heavily on the 
compilation of training data sets, which demand large scale and accurate experiments.  
Another direction is to use the current impact analysis methods to investigate the relationship 
between SNPs and complex trait disease susceptibility. Until recently, complex disease 
studies primarily relied on GWAS using microarray technology.
211
 Increasingly these 
methods are combined with follow-up studies, sequencing around identified disease 
susceptibility loci, and in some cases, making use of whole genome sequence data.
16; 20
 The 
detailed information from sequencing allows all possible causal variants within a region to be 
identified, including rare variants. Linkage disequilibrium effects make it difficult to identify 
the likely causative variants in a locus directly, even when complete sequence is available, 
and the impact analysis methods should prove useful in narrowing choices among the 
missense Single Nucleotide Variants (SNVs).  
As complete genome sequencing becomes more common, broader interpretation of the 
phenotypic relevance of SNVs is becoming more pressing. The sequencing of a single 
individual‟s genome typically generates 2.5-3 million SNVs.
50; 52; 55; 212
 These data imply each 
individual will have approximately 45000 coding region SNVs, half of which, about 22,000, 
are missense changes. Using the estimated high impact rate of 30% for all population 
SNPs,
32; 34
 approximately 7000 are expected to be high impact. The relatively low MAF of 
high impact SNPs (Figure 5 of Yue & Moult 2006
32
) suggests that most will be heterozygous, 
but never-the-less, some will impact protein function in a dominant manner, and a significant 
number will be homozygous or compound heterozygous within a gene. Thus, missense 
effects alone result in each individual carrying a substantial load of malfunctioning or low 
functioning proteins. As data for full personal genomes become more common, it will be 
possible to use the impact analysis methods to identify SNVs that are potential contributors to 
disease and disease susceptibility in each case.  With such a serious application in view, 




Genome Variation, http://genomeinterpretation.org/) experiments are intended to provide a 




Analysis of the impact of SNVs on protein function provides only the first stage (molecular 
level) in understanding their role in complex trait disease and in cancer. New methods are 
needed to not only examine the consequences at the molecular level, but also to identify the 
complex network features characteristic of disease at higher organizational levels. 
Complexity and nonlinear properties of gene networks are the key features in complex trait 
disease, and dictate the choice of methods. A binary classification may not be the most useful 
output either.  
 
There are a group of dimension reduction methods that aim to find meaningful low-
dimensional data structures hidden in high-dimensional input data. Earlier work developed 
dimension reduction algorithms to prioritize gene-gene interactions (or epistasis) for GWAS 
data
214
 and cancer data
215
. Condensation of huge number of all pairwise gene-gene 
interactions into a much smaller combinations of disease relevant ones has been attempted, so 
far with limited success.  
There are  other dimension reduction algorithms that bypass the measurement of pairwise 
distance, instead consider all K-nearest neighbors and model the local structure distance 
matrix with a fewer number of eigenvectors than the input dimension.
216; 217
 Although these 
have so far mostly been applied in the domain of visual perception, their application to the 







































Supplementary Table S4.1. Summary of data in the proteins with interface 
involvement. A total of 1726 proteins with structural information for at least one 
interface are included in the analysis. Variants are divided into those in immune 
proteins and non-immune proteins. The interfaces are grouped into heteromeric and 
















1726 506722 173492 99145 234085 62992 33867 
Diseases 
mutations 
172 2717 1340 630 747 400 210 
Species variants 104 2944 567 614 1763 496 115 
SNPs 779 1778 411 440 927 207 221 
Immune SNPs 72 343 47 180 116 18 156 
Non-immune 
SNPs 
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